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Abstract
Tau protein is the primary constituent of protein aggregates known as neurofibrillary tangles, a
pathological hallmark of Alzheimer's disease (AD). Previous studies suggest that tau protein may play a
contributing role in neurodegenerative diseases such as AD. Thus characterizing the structural
properties of tau is critical to understanding disease pathogenesis. However, obtaining a detailed
structural description of tau protein has been difficult because it belongs to a class of heteropolymers
known as intrinsically disordered proteins (IDPs). Unlike most proteins, IDPs adopt many distinct
conformations under physiological conditions. In spite of their disordered nature, evidence exists that
such proteins may exhibit residual structural preferences. In this work, models of tau are constructed to
characterize these structural preferences. We begin by performing molecular dynamics simulations to
study the inherent conformational preferences of the minimal tau subsequence required for in vitro
aggregation. To model residual structure in larger regions of tau, we developed a novel method called
Energy-minima Mapping and Weighting (EMW). The method samples energetically favorable
conformations within an IDP and uses these structures to construct ensembles that are consistent with
experimental data. This method is tested on a region of another IDP, p21 Wafl/Cipl/Sdil(14 5 -164 ), for which
crystal structures of substrate-bound conformations are available. Residual conformational preferences
identified using EMW were found to be comparable to crystal structures from substrate-bound
conformations of p21 Wafl/Cipl/Sdil( 14 5 -164 ). By applying EMW to tau, we find disease-associated forms of
tau exhibit a conformational preference for extended conformations near the aggregation-initiating
region. Since an increased preference for extended states may facilitate the propagation of cross-13
conformation associated with aggregated forms of tau, these results help to explain how local
conformational preferences in disease-associated states can promote the formation of tau aggregates.
Finally, we examine limitations of the current methods for characterizing IDPs such as tau and discuss
future directions in the modeling of these proteins.
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Chapter 1: Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive
memory loss, cognitive dysfunction, and behavioral disturbances [3]. The disease has a high
prevalence, afflicting approximately 18 million people worldwide and is the most common cause
of senile dementia [4]. The two pathological hallmarks of Alzheimer's disease are extracellular
protein aggregates of amyloid-P (AP), known as amyloid plaques, and intracellular protein
aggregates of tau protein, known as neurofibrillary tangles [5]. Much data suggests that the
proteins which constitute these aggregates, A3 and tau, also play a role in disease pathogenesis
[6-10]. A structural description of these proteins is required to understand the conformational
transitions accompanying aggregation into potentially toxic forms and to assist in the design of
therapeutics targeting these proteins [ 11].
Despite that the majority of AD research has focused on AP, much evidence suggests that tau
dysfunction contributes to disease progression in AD [6, 7, 12, 13]. Tau protein also plays an
important role in a related family of neurodegenerative diseases, known as tauopathies, which
are neurodegenerative disorders characterized by pathological aggregation of tau [14]. Tau
protein belongs to a class of heteropolymers known as intrinsically disordered proteins (IDPs)
[11]. These proteins are sometimes referred to as natively unfolded proteins (NUPs) or
intrinsically unstructured proteins (IUPs). In contrast to most proteins, which fold into a unique,
three-dimensional structure or at least contain large regions of structure, IDPs fluctuate between
many distinct conformations under physiological conditions. Presently there are no existing
experimental methods to fully characterize the set of structures populated by these proteins.
In this work, we combine biophysical modeling and conformational sampling approaches
with published experimental measurements to characterize the structural properties of tau
protein. Thus, one can obtain detailed structural insights that are not available from experiments
alone. The thesis is organized as follows:
Chapter 2 provides an overview of recent experimental and modeling approaches for
characterizing structural properties of IDPs involved in neurodegenerative diseases.
Chapter 3 discusses molecular dynamics simulations performed on a peptide corresponding
to a key tau subsequence which is required for aggregation in vitro. There were two motivations
for this study. First, conformational preferences of this subsequence were of inherent interest due
to its importance in tau aggregation. Second, these simulations were used to evaluate implicit
solvent models for the purpose of sampling conformational minima. Using these methods, we
find that the aggregation-initiating sequence has an intrinsic propensity for extended
conformations. Furthermore, we identified an implicit solvent potential for efficient sampling of
conformational minima.
In order to identify residual conformational preferences in larger regions of tau, we
developed a novel semi-empirical method for constructing conformational ensembles of
intrinsically disordered proteins. This protocol is discussed and used in the studies described in
chapter 4 and the appendix. We initially tested the method on a region of the intrinsically
disordered protein p 2 1 Wafl/C ipl /Sd i l (appendix). Unlike tau, p2 1 Waf l /Cipl/Sdi l is an intrinsically
disordered protein for which crystal and NMR structures of substrate-bound subsequences exist
[15, 16]. Thus, we compared structural properties described by our method against known bound
conformations. This analysis showed that local conformational preferences in the unfolded state
of p2 1Wafl /Cipl/ Sdi identified by our method were comparable to structured substrate-bound
conformations. This work was performed with Veena Venkatachalam, an undergraduate student,
and in collaboration with James Chou [17]. The method was then applied to both wild-type and
disease-associated mutant forms of tau protein (Chapter 4). The resulting conformational
ensembles describe how changes in local conformational preferences between normal and
disease-associated forms of tau can contribute to differences in their propensity to aggregate.
Recently, additional structural data for the microtubule-binding repeat domain of tau
(referred to as K18) have been published [18, 19]. Chapter 5 discusses work to incorporate these
data into models of K18. In addition, we attempted to test an alternate modeling approach which
does not require fitting to experimental data. This model is based on the hypothesis that
conformational preferences of sequentially long-range positions can be approximated as being
independent. In Chapter 6, we discuss limitations of current experimental and modeling
approaches to characterizing structure in tau (and IDPs in general) and future directions for
research.
Chapter 2: Finding Order within
Disorder - Elucidating the Structure
of Proteins Associated with
Neurodegenerative Disease
(This work was published as A. Huang and Stultz CM., "Finding Order within Disorder - Elucidating the
Structure of Proteins Associated with Neurodegenerative Disease," Future Medicinal Chemistry
(accepted), 2009.)
Abstract
A number of neurodegenerative disorders such as Alzheimer's disease and Parkinson's
disease involve the formation of protein aggregates. The primary constituent of these aggregates
belongs to a unique class of heteropolymers called intrinsically disordered proteins (IDPs).
While many proteins fold to a unique conformation that is determined by their amino acid
sequence, IDPs do not adopt a single well-defined conformation in solution. Instead they
populate a heterogeneous set of conformers under physiological conditions. Interestingly, despite
this intrinsic propensity for disorder a number of these proteins can form ordered aggregates both
in vitro and in vivo. As the formation of these relatively ordered aggregates may play an
important role in disease pathogenesis, a detailed structural characterization of these proteins and
their mechanism of aggregation is of critical importance. However, given their inherent
complexity and heterogeneity, new methods are needed to decode the diversity of structures that
make up the unfolded ensemble of these systems. Here we discuss recent advances in the
structural analysis and modeling of IDPs involved in neurodegenerative diseases, and outline
future directions in the development of therapies that are designed to prevent their aggregation.
Introduction
Many proteins encoded by the human genome fluctuate about a well-defined three
dimensional structure during their biological lifetimes. This observation has lead to the often
stated, and amply validated, structure-function paradigm; i.e., a protein's function is determined
by its three dimensional structure [20]. However, it is increasingly apparent that a number of
proteins in the human proteome do not adopt well defined three-dimensional structures under
physiologic conditions [21-23]. These intrinsically disordered proteins (IDPs) stand in stark
contrast to the archetypal structure-function paradigm and therefore represent unique and
interesting biological heteropolymers whose study may lead to insights into the relationship
between amino-acid sequence and structure. More importantly, deciphering the relationship
between structure and function for these systems is not purely an academic exercise. Many
neurodegenerative diseases have been associated with abnormal/excessive aggregation of IDPs.
Alzheimer's Disease, one of the most prevalent forms of Dementia in the US, is associated with
two types of IDP aggregates. Extracellular aggregates known as senile plaques are composed of
amyloid-3 peptide, a cleavage product of amyloid-precursor protein (APP) (Figure 1, APP) and
intraneuronal aggregates, known as neurofibrillary tangles (NFTs), are composed of the IDP tau
protein (Figure 1, tau) [24, 25]. Parkinson's Disease associated Dementia (PDD) or Dementia
with Lewy Body Disease (DLB) is the second most common form of dementia and is
characterized by aggregates, known as Lewy bodies, which are primarily composed of the
intrinsically disordered protein a-synuclein (Figure 1, a-synuclein) [26].
Common forms of key proteins in neurodegenerative diseases
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Figure 1 Primary structure of the common isoforms of proteins involved in neurodegenerative diseases.
Amyloid Precursor Protein contains a 40-42 residue segment (A|340/42) that is found in senile plaques and
aggregates of tau protein are found in Neurofibrillary tangles. Both types of aggregates are found in patients
with Alzheimer's Disease. Aggregates of a-synuclein are found in patients with patients with Parkinson's
Disease and Dementia with Lewy Body Disease.
Substantial evidence exists to suggest that these IDPs play an important role in these
neurodegenerative diseases. First, several studies argue that mutations in APP, tau, and a-
synuclein result in hereditary forms of neurodegenerative diseases [27-31]. In animal and cell
models, mutant forms of APP and tau, or overexpression of these proteins, results in disease
phenotypes [6-8, 32, 33]. Neurofibrillary tangles as well as levels of soluble AP oligomers, are
correlated with progression of AD and promisingly, disruption of aggregation has been found to
prevent or reverse disease progression in cell and animal models [6, 7, 9, 12, 34, 35]. Taken
together, these data suggest that pathological aggregation of these intrinsically disordered
proteins may be a key contributor to these disease processes.
IDPs typically fluctuate between different conformations under physiologic conditions,
leading to an ensemble of structurally dissimilar states. Recent studies, however, suggest that the
aggregation process of a number of IDPs, like AP, tau and a-synuclein, involves the formation of
partially folded intermediates that self associate to form complexes that contain considerable
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cross p-structure [36, 37]. Hence the aggregation process for many of these IDPs is quite
complex. Given the likely importance of aggregation to neuronal degeneration and dysfunction,
understanding the nature of the unfolded state of these proteins and their ability to form ordered
aggregates is an important fundamental problem in biology and medicine. Furthermore, a
comprehensive understanding of the aggregation mechanism of these heteropolymers may lead
to novel therapies that prevent their aggregation.
Typically, structural information on proteins is obtained using well-established techniques.
In order to solve a protein's structure with x-ray crystallography (the most commonly used
method for structure determination), the protein must first be crystallized so that a meaningful
diffraction pattern can be obtained. Crystallization is successful when the different protein
molecules in the crystal have nearly identical structures and orientations. In the case of IDPs
however, the inherent structural heterogeneity of the system makes successful crystallization not
possible. Clearly protein x-ray crystallography, which effectively determines the average of the
different structures in the protein crystal, is not an appropriate technique to study the structure of
IDPs, which are inherently heterogeneous. Any useful characterization of the structure of these
proteins must therefore capture the inherent diversity of structures that populate the unfolded
ensemble. It is in this regard that physically based models can play an important role. Computer
simulations of proteins, for example, have shed considerable light on the aggregation mechanism
of polygutamine containing proteins, which are intrinsically disordered [38, 39]. Moreover,
approaches that combine experimental results with computational methods can be used to
construct detailed structural models of the unfolded state of IDPs. The resulting insights
contribute to our understanding of the aggregation process and may ultimately be useful for
designing compounds that prevent IDP aggregation.
In this chapter we discuss methods and strategies for constructing detailed models of the
unfolded state of IDPs that are believed to play a role in neurodegenerative disorders. We
illustrate how such information has shed light on the pathogenesis of aggregation and suggest
how these insights can be used to initiate new drug design strategies.
Characterizing the Structure of an Intrinsically
Disordered Protein
The early work of Anfinsen coupled with the advent of protein crystallography helped to
establish the paradigm that each amino-acid sequence is associated with a unique three
dimensional structure [40-42]. In this context, structural characterizations of proteins have an
unambiguous meaning; i.e., characterization of a protein's structure involves finding this unique
conformation. As more IDPs have been discovered this classic paradigm must be recast in a
form that is appropriate for systems that do not adopt a well-defined structure in solution. In a
sense the central question for these systems becomes: what does it mean to characterize the
structure of an IDP?
Early views of the unfolded state of proteins described disordered polypeptides as random
coils devoid of structural preferences [43]. However, recent reviews of molecular volume
characteristics and other properties of intrinsically disordered proteins have made it clear that
there exists a spectrum of disorder and that a generic random coil is not always an adequate
description for the structural properties of IDPS [21-23]. Molecular volume scaling properties
range from highly disordered random-coil like conformations to relatively collapsed premolten
globule like states [22, 23]. In studying these proteins, several questions commonly arise. Is a
featureless random coil adequate to explain the experimental measurements? Are there global
conformations that are strongly preferred? Are there local conformational preferences? Most
importantly - how are conformational preferences related to protein function, aggregation, and
disease pathogenesis?
Insights into the physical basis of the structural heterogeneity within IDPs can be garnered
from a review of the protein folding literature. It has been suggested that proteins that adopt a
well-defined structure in solution fold on "funnel shaped" energy surfaces [44, 45]. The folding-
funnel hypothesis postulates that in spite of the astronomical number of conformations associated
with the unfolded state [46], the conformational free energy surface is shaped like a funnel and
this drives the protein towards its folded conformation (Figure 2A). Although there are many
different possible conformations for the protein, the shape of the surface ensures that the protein
reliably folds to a unique region of conformational space, corresponding to the folded state [45,
47]. Unlike the conformational free energy landscape of a natively folded protein, the
conformational free energy landscape of an intrinsically disordered protein lacks a prominent
folding funnel (Figure 2B) [23]. As such, the protein can adopt multiple low energy
conformations on the energy surface, corresponding to local energy minima. For folded proteins,
characterization of the structure entails finding the low energy conformer at the basin of the
funnel (Figure 2A). By contrast, characterization of the unfolded state of an IDP necessarily
encompasses an enumeration of its accessible low energy conformations.
A B
Figure 2 Schematic of a conformational free energy landscapes. A) The conformational free-energy landscape
of a folded protein exhibits a deep well-defined minimum corresponding to the native conformation. B) The
conformational free-energy landscape of an intrinsically disordered protein lacks a deep free-energy
minimum. Thus the "native state" consists of an ensemble of interconverting conformations.
It is important to note that enumerating accessible low energy states is not equivalent to
enumerating all possible conformations. For many systems the most prevalent structures span a
range that may exhibit strong conformational preferences. In the case of tau protein, for
example, there are data to suggest that some local structural motifs are strongly preferred over
others [19, 48, 49]. Studies such as these suggest that the unfolded state of IDPs have their own
taxonomy and therefore may exhibit distinct preferences for particular structural states.
Consequently, a comprehensive characterization of the unfolded state of an IDP should include a
description of these conformational preferences.
It is also noteworthy that not all structures within a given unfolded ensemble are created
equal. There are data to suggest that for many systems aggregation proceeds along a nucleation
growth mechanism that is facilitated by the formation of partially folded intermediates [36, 50].
Structures within the unfolded ensemble that have characteristics similar to these partially folded
intermediates may facilitate the aggregation process in vitro (Figure 3). For such systems a
central problem in the characterization of the unfolded state is the identification of such
aggregation prone conformers. Once identified and isolated, one can design molecules that
specifically prevent the self association of these problematic structures.
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Figure 3 Hypothesized pathological aggregation pathway of an intrinsically disordered protein that forms
amyloid fibrils. The circled structure represents an aggregation-prone conformer within the native unfolded
ensemble. Conformers in the unfolded ensemble can act as partially folded intermediates, which are
aggregation-prone. These aggregation-prone conformers initiate formation of soluble oligomers. Oligomers
are extended and stabilized by the addition of monomers to form an insoluble amyloid fibril. We note that
the structure of soluble oligomers are not known, therefore the above mechanism remains speculative.
Current Experimental Approaches to Studying
Intrinsically Disordered Proteins
The experimental characterization of intrinsically disordered proteins is a relatively nascent
field. Several excellent reviews that summarize current experimental methods for studying
intrinsically disordered proteins have recently been published [50-53]. A number of methods
have been fruitfully applied to gain insights into the unfolded ensemble of IDPs. While a vast
and diverse array of methods have been utilized, including optical spectroscopy, small-angle X-
ray scattering (SAXS), and dynamic light scattering, the most popular methods have been based
on nuclear magnetic resonance (NMR) spectroscopy [51, 54]. [55]. While much of the remainder
of this section focuses on NMR-based measures, we note that many other techniques provide
complementary information that can yield important insights into the nature of the unfolded
state. For example, optical spectroscopic methods can greatly complement NMR-derived
measurements, as the timescales and experimental conditions of such optical spectroscopic
methods are different from NMR-based methods. In fact, initial determination of whether a
protein is intrinsically disordered is frequently accomplished using circular dichroism (CD), an
optical spectroscopic method [55]. A more complete discussion of the relative strengths of other
methods can be found in the aforementioned references [50-53].
A number of different NMR-based measures have been used to glean information about the
unfolded state of IDPs. These methods include an array of nuclear magnetic resonance (NMR)
techniques. For example, Nuclear Overhauser Effect (NOE) measurements are used to determine
short-range contacts preserved in the unfolded ensemble and chemical shifts, residual dipolar
couplings (RDCs) and 3J couplings can provide residue-specific information regarding local
conformational preferences. Methods such as pulse-field gradient diffusion - in addition to non-
NMR techniques such as SAXS - are used as standard measures for comparing and contrasting
the protein of interest with the standard random coil models.
The existence of multiple experimental methods that can be applied to IDPs has enabled
important insights regarding the structural characteristics of these systems [52]. Nevertheless, it
is important to realize that most experimental measurements represent ensemble averages over a
large number of distinct conformations. Therefore it is often difficult to draw detailed
conclusions about the types of conformers that populate the unfolded ensemble from these data
alone. Even so, it is becoming clear that some experimental metrics are much more useful than
others. NOEs can be quite useful in the analysis of protein structure because they yield precise
distance measures between residues that might be separated in the amino-acid sequence [56].
Yet, given the relatively short internuclear distance that is explored by NOE experiments, only
residues that remain in very close contact in the majority of structures in the ensemble will give
reliable NOE data. In particular, NOEs that are indicative of long range contacts are usually not
observed in IDPs. By contrast, paramagnetic relaxation experiments can yield distance measures
that are significantly larger and therefore these data may be quite useful for identifying long
range contacts that are preferentially populated in an unfolded ensemble [57].
Recent data suggest that RDC measurements may also be particularly useful for
understanding the nature of the unfolded state. Indeed, it has been argued that RDCs encode
information about the average global structure of the protein [58, 59]. The greater information
content of RDCs arises from the fact that prior to measuring RDCs, proteins are placed in an
alignment medium, where the exact alignment of the protein is determined by the protein's
global structure [59, 60].
More recent non-NMR based experimental methods have employed disulfide scrambling
assays to capture particular conformers within the unfolded state [61]. The underlying idea is
outlined in Figure 4. In this example, cysteine residues are introduced into an IDP at two
positions. In Figure 4 the protein is depicted as being able to adopt three distinct conformations,
Ci, C2 and C3. The introduction of cysteine residues in the sequence is done to facilitate
disulfide bond formation in state C3, but not in conformers Ci and C2. Hence under oxidizing
conditions a disulfide bonded form of conformer C3 (conformer C4) is formed. Since the
formation of structure C4 is essentially irreversible, the equilibrium becomes shifted towards this
"trapped" state by the laws mass action. Therefore, if we allow the redox reaction to proceed for
a significant period of time, a solution that is enriched in conformer C4 will be obtained. This
approach, which has been pioneered by Chang, has been applied to a-synuclein [61, 62]. As
some of the trapped disulfide-bonded isomers had an increased propensity to aggregate relative
to the wild-type protein, these data argue that the unfolded state of a-synuclein in solution
contains a variety of different conformations in solution, where some conformations are more
aggregation-prone than others. One drawback of their approach is that the authors had no model
for the unfolded state, the residues to mutate into cysteine were not chosen based on structural
considerations; e.g., residues known to be phosphorylated in wild-type a-synuclein were mutated
[61]. Clearly a more detailed model of the unfolded state would help to effectively identify
aggregation prone conformers.
Oxidizing
Agent
- ----------------------Redudng Conditions ---------------------- Agent
Ci C2 Cs Ct
Figure 4 Trapping of specific conformations within an unfolded ensemble
One challenge facing many of these experimental methods is the sensitivity of the unfolded
ensemble to perturbations in experimental conditions. Experimental conditions often need to
deviate from physiological conditions to optimize the signal to noise ratio for a given
experimental measurement. Varying experimental conditions to study folded proteins is widely
employed and generally well founded. Most notably, crystallization conditions for folded
proteins may deviate substantially from physiological conditions, yet the solved structures have
been shown to be physiologically relevant in a many cases (e.g., [63, 64]). However, the case
may be quite different for an IDP. In the absence of a deep native basin at the bottom of a
folding funnel on the free energy landscape, it is unclear to what extent the distribution of
conformers will be perturbed by even minor changes to the protein's chemical environment.
Thus, independent measurements made on the unfolded ensemble may reflect different
ensembles and these ensembles may also differ from the conformational ensemble under
physiological conditions. For example the conformational equilibrium of a-synuclein is
substantially changed by modifying buffer conditions [65, 66].
In short, the relevance of in vitro studies to the structure of these proteins in vivo remains an
open question. Nevertheless, methods that use data obtained from in vitro studies to guide the
development of unfolded ensembles provide a rigorous framework to develop and test methods
for modeling the unfolded state. Moreover, these studies lead to testable hypotheses that can be
extended to in vivo studies.
Methods for Constructing Models of the Unfolded
Ensemble
Intuitions derived from an analysis of experimental measurements made on folded proteins
can lead to misinterpretation when these same methods are applied to an intrinsically disordered
protein. Model based approaches that incorporate experimental measurements to aid in the
analysis of experimental observations allow one to interpret experimental findings within the
context of structural ensembles that describe the types of conformers that populate the unfolded
ensemble. As such, these methods have greatly improved our understanding of the unfolded
states of proteins and have clarified our understanding of experimental data.
One early method used to model the unfolded state of biological heteropolymers is the
statistical coil model. These models are called statistical coil models because their ensembles are
defined by a set of random coil structures sampled from residue-specific statistical distributions.
They typically account for a very limited set of factors in the unfolded state; e.g. residue-specific
backbone dihedral angle propensities that are parameterized based on loop regions from the
protein data bank and steric clashes [67, 68]. From these distributions a conformational ensemble
for any IDP can be created by sampling conformations for each residue. These models have been
used to interpret measurements made on a number of IDPs such as tau protein and in many
instances qualitative agreement with experimental measurements has been obtained [19, 67, 68].
Nevertheless, the simplicity of the statistical coil model is both a strength and a weakness. In
general, the residue-specific conformational distributions fully parameterize the model - there is
no additional system-specific parameter fitting required. At the same time it is difficult to gain
system-specific insight from the model because conformational correlations between distant
residues in the sequence are not captured. In addition, it has been shown that the aggregation
properties of some IDPs can be dramatically altered by introducing single residue changes in the
sequence (e.g., [69-72]). NMR based measurements for such mutant sequences exhibit very
small changes relative to the wild-type protein [70, 72]. In these cases it is not clear that these
statistical models, which typically have qualitative agreement with experiment, is sufficient to
capture ensemble differences between wildtype and mutant proteins that correlate with distinct
aggregation properties. Consequently, other methods that yield more quantitative agreement
with experiment are needed to decipher the relationship between small changes in the
experimentally determined quantities and aggregation behavior.
Molecular dynamics simulations have been employed to generate low energy structures that
may represent the unfolded state ensemble. Extended-ensemble algorithms such as replica
exchange can aid in efficiently sampling conformational transitions yielding a heterogenous set
of structures [73-75]. In some instances (as we discuss in the next section), these methods have
yielding important insights into the types of structures that populate the unfolded state.
However, inaccuracies in the underlying potential function and the approximate nature of the
solvent model can make reliable agreement with experiment difficult.
Recently a number of approaches have been developed to create models that yield improved
agreement experiment [76]. While they differ in their details, most of them have similar
overarching themes. Many begin by first creating a library of protein conformations using a
conformational sampling algorithm (e.g., Monte Carlo, Molecular Dynamics, etc.) which can
then interpreted as the ensemble. In some cases, the resulting set of sampled conformations is
then used to generate subsets that represent the unfolded ensemble. In addition to a set of
conformers in the unfolded ensemble, some methods also associate a weight with each
conformer. A conformer's weight represents the probability that the protein in question adopts
that specific conformation. Sampling and initial weight assignment is then followed by
additional model optimization to fit the experimental data. Examples of these approaches are the
ENSEMBLE algorithm [77, 78], sample-and-select (SAS) [79], ensemble optimization method
(EOM) [80], and energy-minima mapping and weighting (EMW) method [49]. In each case,
construction of the ensemble is formulated as an optimization problem where the function to be
minimized captures the difference between ensemble-averaged structural quantities of the model
and the measured experimental observables.
As the structural ensemble is explicitly represented as a discrete set of structures, this type of
model can predict any experimental quantity as long as there is a function S (X,) that maps each
conformation, X,, in the ensemble to an experimental measurement. For example, S (X,) can be
the chemical shift or RDC of a given residue in the protein and therefore obtained using a
number of established algorithms, which calculate chemical shifts and residual dipolar couplings
associated with a particular structure [2, 81, 82]. Once the experimental value in question can be
calculated for a given conformer in the protein, the ensemble average predicted value can be
expressed as a sum of the contributions due to each conformer:
N
SE (Wi, X i) = w,S(X) (2.1)
i=1
where the weight, w,, is the probability that the protein adopts conformation X,, and
SE (w, X,) is the ensemble averaged value. The summation goes over the set of N structures in
the ensemble. Ensemble members are chosen to minimize the error between the calculated
ensemble averaged value and the corresponding experimentally determined value, which is
typically obtained on a solution containing the IDP of interest. In algorithms such as SAS and
EOM in which each structure is given equal weight and structures are sampled from a
conformational library, this can expressed as constraining all values of wj to evaluate to 1/N or
0, where N is the number of selected conformers. Furthermore, the requirement that a limited
number of conformers is used to fit the experimental data, can be expressed by limiting the
number of weights, wj, that are nonzero. Several approaches have been utilized in the
optimization of this objective function, including simulated annealing and genetic algorithms
[79, 80].
There are two primary difficulties with these approaches. First, the conformational library
must encompass the most prevalent conformations. As ensemble members are chosen from the
conformational library, it will not be possible to obtain a physiologically relevant solution if the
originally library does not contain conformers that are present with high probability in the
unfolded ensemble. The second difficulty is the degeneracy of the solution space. Given that
accurate modeling of an unfolded protein is an undetermined problem, it is likely that there are a
number of different ensembles that agree with any given set of experimental data. By making
additional independent measurements, one can reduce the size solution space by many orders of
magnitude, as was shown by Choy et al for a small system [77]. As yet, however, a comparable
analysis has not yet been performed for a full protein, which has a substantially larger number of
degrees of freedom. Another approach to addressing the problem of degeneracy is to generate
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multiple solutions that are consistent with a given set of experimental data and to find
characteristics common to all solutions [49]. In other words, given the underdetermined nature
of the problem, it is not clear how to determine when one has the "correct" ensemble. However,
structural motifs that consistently appear in all independent ensembles are likely to also be
present in the "correct" ensemble.
The application of these methods has lead to important insights on the nature of the unfolded
state of several IDPs and their mechanism of aggregation. Below we highlight how these
methods have been applied to distinct IDPs.
Modeling IDPs Associated with Neurodegenerative
Disorders
Amyloid-fi
Alzheimer's disease (AD) is the most common form of senile dementia, characterized by
memory loss, personality changes, and global cognitive dysfunction [10]. AD is associated with
two pathological hallmarks - extracellular amyloid plaques and intracellular neurofibrillary
tangles composed primarily of amyloid-P peptide (AP) and hyperphosphorylated tau protein,
respectively [14, 83, 84]. Both AP and tau are intrinsically disordered proteins. The IDP AP is a
39 to 43 residue peptide produced by cleavage of amyloid precursor protein (APP) by p-secretase
and y-secretase [36, 85] (Figure 1).
Despite the fact that AP is intrinsically disordered, it can be made to adopt a relatively
restricted set of conformers under the right experimental conditions. For example, structural
ensembles were constructed from NOE data obtained on AP(1-40) in an aqueous sodium dodecyl
sulfate (SDS) environment [86]. APP is a membrane-bound protein and A3 is believed to include
membrane-spanning residues of APP; thus the micelle-bound structure may reflect the initial
conformation of A3 immediately after cleavage from APP. While these data suggest that that
AP(1-40) contains residual helical structure in a membrane environment, they are not likely to be
representative of the aqueous monomeric structure which aggregates into amyloid fibrils.
Structures derived from AP(10-35) in solution are a better mimic the physiologic environment of
monomeric AP, though the exclusion of terminal residues may affect the conformational
ensemble [87]. NMR data on AP(10-35) in solution have been obtained and suggest that the
structure of peptide in solution is relatively compact and devoid of any secondary structure [87].
The structure also contains notable hydrophobic clusters at its core and also on its surface. In a
later work, Hou et al measured 1H, '5N, and 13C chemical shifts for AP40 and AP42 [88]. This
study identified local conformational preferences for P-strand structure in hydrophobic regions
(17-21 and 31-36) and turn conformations (7-11 and 20-26). While such studies shed light on
potential conformers of AP or ensemble averaged characteristics, they also may not fully capture
the conformational heterogeneity of the disordered protein.
Due to its relatively small size, molecular modeling studies of AP can be performed rather
efficiently, yielding insights into the structure of, and transitions between its monomeric and
aggregated forms. Extensive molecular dynamics simulations of a truncated form of AD (residues
10-35) were performed to obtain a conformational ensemble of the peptide in solution [89]. The
model ensemble was compared with an NMR structure of AP(10-35) in solution that was
obtained from NOE measurements. Quite remarkably, the ensemble obtained by simulation was
able to reproduce the majority of the NOE constraints used for Af3(10-35). More importantly,
the ensemble derived from the simulations was structurally more diverse than the original
ensemble modeled from the NOE constraints alone. These results exemplify the difficulty of
interpreting NOE-derived model ensembles of intrinsically disordered proteins as there may exist
a number of different ensembles that agree with a given set of experimental data.
Several studies have examined the transition of AP monomers into aggregation-inducing
intermediates. Since these studies suggest that cleavage of APP into AP occurs in early
endosomes, Khandogin and Brooks used constant pH molecular dynamics (CPHMD) to probe
the effect of endosomic pH on the conformational ensemble of AP [90]. These simulations found
a pH dependent transition of the central hydrophobic residues of AP from helical to P-turn
conformations, and suggest that the conformational ensemble at endosomal pH includes exposed
hydrophobic residues and p-structure, properties consistent with aggregation initiation. These
findings support the notion that endosomal pH may play a role in facilitating pathological
conformational transitions of AP. Xu et al examined the conformational transition of AP from a
helical membrane-bound form into an aqueous 1-sheet rich intermediate and identified four
glycine residues critical to this conformational transition.
Numerous coarse-grained and all-atom molecular dynamics simulations have also been used
to explore the transition of AP from monomers to oligomers and examine the stability of
aggregate species [91-96]. Fawzi et al utilized coarse-grained molecular dynamics simulations,
showing the different effects of disease-associated mutants on the structure and stability of AP(1-
40) protofibrils [93]. All-atom simulations performed on a critical region of AP (residues 16-22)
to examine oligomer growth show that small oligomers undergo a substantial amount of
rearrangements to accommodate the addition of a monomer and that addition of a monomer
occurs during a two-phase mechanism consisting of fast association, followed by a slow
conformational rearrangement [92]. The study also suggests that oligomer extension is distinct
from fibril extension, as fibril extension involves far smaller conformational changes to the
aggregate species. Taken together, these studies provide a detailed view of oligomerization as a
distinct, more dynamic process than fibril extension. Such a distinction is critically important, as
there are data to suggest that oligomers, and not fibrils, may be the critical toxic species in AD
[9].
ar-synuclein
Parkinson's disease (PD) is characterized by an involuntary tremor, muscle stiffness,
bradykinesia (slow movement), and postural instability [97]. Many patients with PD also have
cognitive dysfunction that can be a major cause of morbidity and mortality. These patients can
be characterized as having either Parkinson's Disease Dementia (PDD) or Dementia with Lewy
Body Disease (DLB) [98]. In both cases, the pathological hallmark consists of intraneuronal
protein aggregates known as Lewy Bodies [97]. As with AD, familial forms of PDD or DLB
have been helpful in providing genetic data to implicate proteins that may have a causative role
in the disease. A key gene associated with familial forms of Parkinson's disease encodes the a-
synuclein protein, an intrinsically disordered protein, which is also the primary protein species
present in Lewy bodies [99]. a-synuclein appears in 3 isoforms but is predominantly found in a
140 residue isoform and is primarily expressed in neural tissue [100]. a-synuclein contains a
central portion - the non-amyloid component (NAC) region - which is believed to play an
important role in the formation of protein aggregates [101, 102]. Interestingly, the NAC region
fragment is also a secondary constituent of amyloid plaques in Alzheimer's disease [103, 104].
Despite its intrinsic disorder, a-synuclein self-associates to form fibrils that contain
considerable cross p-structure [37, 105, 106]. Several studies suggest that fibrillization involves
a nucleation growth mechanism that involves interactions between ordered segments in the
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protein [70, 107]. Spin labeling and EPR studies on a-synuclein fibrils suggests that the central
portion of the molecule, which contains the NAC(8-18) fragment, is folded into a core that
contains significant p-structure, while the C-terminus of the molecule is disordered and the N-
terminus is structurally heterogeneous [108, 109]. The importance of p-structure in the
aggregation process is supported by the observation that mutations which decrease the propensity
for p-structure can reduce the ability of a-synuclein to aggregate in vitro [110]. While these
observations have advanced our understanding of the aggregation process, they do not directly
provide information about the types of conformers that populate the unfolded ensemble of
monomeric a-synuclein in solution.
Recent studies using atomic force microscopy on a-synuclein monomers confirm that
unfolded ensemble contains different classes of structures where some conformers have a
relative abundance of P-like structure - a structural motif thought to play a role in the
aggregation mechanism [66]. Further insights into the unfolded ensemble and the aggregation
process have been obtained from studies on a-synuclein mutants. As previously discussed, a
recent work engineered cysteine mutations into a-synuclein and subsequently used a disulfide
scrambling assay to capture isomers with particular disulfide bonding patterns [61]. Since the
authors had no model for the unfolded state, the residues to mutate were not chosen based
structural considerations. For example, residues known to be phosphorylated in wild-type a-
synuclein were mutated [61]. As some of the observed isomers had an increased propensity to
aggregate relative to the wild-type protein, these data argue that a-synuclein contains a variety of
different conformations in solution, where some conformations are more aggregation-prone than
others. Clearly a more comprehensive understanding of the mechanism underlying a-synuclein
aggregation and fibril formation requires detailed knowledge of the conformations that populate
the unfolded state.
A recent study combined data from spin-label NMR experiments and restrained molecular
dynamics simulations to model the unfolded state of a-synuclein [57]. Distance restraints arising
from paramagnetic relaxation enhancement experiments were incorporated into standard MD
simulations to develop a model of the unfolded ensemble. These data suggested that a-
synuclein is more compact than would be expected using a standard random coil statistics - a
finding consistent with previous experimental observations [107]. More importantly, it was
demonstrated that this compactness was driven by long range contacts in the protein [57]. A
subsequent study used a statistical coil model to generate a model for the unfolded ensemble.
Those results were then compared with RDCs from a-synuclein [58]. While qualitative
agreement with experiment was obtained for the central region of the protein, relatively poor
agreement was noted for residues near the N and C-termini. It was demonstrated that significant
improvement could be obtained by including long range contacts between residues near the N-
terminus and the C-terminus - a finding consistent with the notion that that long range contacts
exist in the unfolded state [58]. Interestingly, data obtained from paramagnetic relaxation
measurements made in the presence of substances known to promote aggregation in vitro,
suggest that these long range interactions are released under aggregation-promoting conditions
[111]. It has therefore been suggested that the release of long range contacts leads to the
exposure of hydrophobic regions that can then facilitate self-association.
Tau Protein
Tau protein naturally occurs in six isoforms (the largest of which is 441 residues in length)
and belongs to the family of microtubule-associated proteins. The C-terminal region of tau
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contains four imperfect microtubule binding repeats (Figure 2) [112]. As many disease-
associated mutations are found in this domain, it is thought to play an important role in the
misfolding and aggregation of tau into neurofibrillary tangles [113]. Alongside AD there is an
entire class of diseases, known as tauopathies, which are neurodegenerative disorders
characterized by pathological aggregation of tau [14].
There are many unanswered questions regarding the mechanism underlying the formation of
tau aggregates. One issue is the role of phosphorylated tau in the formation of NFTs.
Aggregated tau typically exists in a highly phosphorylated form [114]. Although nineteen
different phosphorylation sites on tau have been identified, little is known about the precise role
that phosphorylated isoforms have on the aggregatory process and cellular death [115]. There
are data to suggest that phosphorylation at specific sites can affect the kinetics and
thermodynamics of tau-microtubule binding, resulting in a decreased affinity of tau for
microtubules [116]. In addition, mutations of tau that mimic the effects of phosphorylation at
specific sites can enhance the formation of tau fibrils in vitro [117, 118]. These data suggest that
phosphorylation may directly play a role in tau aggregation in vivo and in vitro. Methods that
assess the effect of phosphorylation on the structure of tau may help to decipher the complex role
that phosphorylation plays in tau pathology. In addition to hyperphosphorylation, a number of
missense mutations in tau have been linked to neurodegenerative disorders that bear the
pathological hallmark of increased NFT formation [119]. While many of these mutations have
multifaceted effects on tau expression, a number of them can also promote tau aggregation in
vitro [120, 121]. Consequently, deriving methods that can model the unfolded state of tau may
help to decode the role that structural changes in the unfolded ensemble play in the development
of NFTs.
Tau protein was initially identified as an intrinsically disordered protein through the use of
CD measurements, SAXS, and Fourier Transform Infrared Spectroscopy (FTIR) [55]. Analysis
of secondary chemical shifts and modeling studies of WT and disease-associated mutant forms
of the tau suggest local structural preferences such as extended structure in aggregation-initiating
regions of the microtubule-binding-repeat domain [48, 49, 122-124]. These experiments provide
insight into the gross average structural properties of tau. However, more detailed models of the
unfolded state are needed to obtain a more complete picture of structural propensities within the
unfolded ensemble.
RDC measurements were made on constructs representing the microtubule-binding repeat
domains of tau and a statistical coil model was used to interpret the RDC measurements [19].
However, the model was unable to fully reproduce the experimental data and additional
molecular dynamics simulations were used to re-parameterize the residue-dependent
distributions, yielding calculated RDC values that were in agreement with experiment. The
resulting structures suggested that short stretches in each repeat domain adopted turn
conformations with relatively high frequency. These data demonstrate that the coupling of NMR
data and molecular simulations can lead to fruitful insights into local conformational preferences
within tau's unfolded ensemble.
IDPs as Targets for Drug Design
Due to increased life expectancies, the prevalence of age-associated dementias such as AD
and DLB is projected to increase substantially [3]. Currently, available therapies for these
diseases only slow the progression of disease or are palliative at best [125]. To date the FDA has
approved five therapies - four cholinesterase inhibitors and an N-methyl D-aspartate (NMDA)
receptor antagonist - for AD [125]. Clearly there is a strong need for the development of novel
therapies for these devastating diseases.
There are substantial data to suggest that aggregated forms of IDPs act as toxic species [9,
26]. Cell and animal models offer a tantalizing glimpse into the therapeutic value of disrupting
aggregation promoting conformations or enhancing protein clearance [6, 7]. In vitro studies have
identified peptides or small molecules which disrupt amyloid-3 and tau aggregation, and that, in
some cases, reduce cell toxicity [34, 35, 126, 127]. There are currently multiple clinical trials of
therapies which aim to disrupt the aggregation of AP or tau protein in AD. Two of the most
advanced drugs in clinical trials which target tau and AP, respectively, are methylionium
chloride (RemberT M), a tau aggregation inhibitor which is currently in phase II clinical trials and
bapineuzumab, a passive immunization anti-AP monoclonal antibody in phase III clinical trials.
Like the study of IDPs themselves, the rational design of drugs targeting IDPs is a relatively
new field. One of the key tools in rational drug design is the use of protein structure in the design
strategy. The field of structure-based drug design (SBDD) aspires to design drugs based on the
3D structure of a target molecule [128]. Clearly this approach is inappropriate for a
conformationally heterogeneous protein. Recently, however, Cheng et al proposed a systematic
approach to targeting of IDPs for drug design [129]. Among other approaches, they suggest
synthesizing a peptide mimic to a hydrophobic target region of the protein. This peptide can bind
the IDP and may stabilize it in a unique conformation that may be suitable for crystallization. In
this way, one can potentially isolate and study specific conformations that design molecules that
help to prevent their aggregation. In principle, once aggregation-prone conformers are
identified, existing structure-based design methods can be applied to design molecules that
prevent the self-association of these problematic conformations [130, 131].
Chapter 3: Conformational
Sampling with Implicit Solvent
Models: Application to the PHF6
Peptide in Tau Protein
(This work was published as A. Huang and C. M. Stultz, "Conformational sampling with implicit solvent
models: Application to the PHF6 peptide in tau protein," Biophysical Journal, vol. 92, pp. 34-45, Jan
2007.)
Abstract
Implicit solvent models approximate the effects of solvent through a potential of mean force
and therefore make solvated simulations computationally efficient. Yet despite their
computational efficiency, the inherent approximations made by implicit solvent models can
sometimes lead to inaccurate results. To test the accuracy of a number of popular implicit solvent
models, we determined whether implicit solvent simulations can reproduce the set of potential
energy minima obtained from explicit solvent simulations. For these studies, we focus on a 6-
residue amino-acid sequence, referred to as the paired helical filament 6 (PHF6), which may play
an important role in the formation of intracellular aggregates in patients with Alzheimer's
disease. Several implicit solvent models form the basis of this work - two based on the
Generalized Born formalism, and one based on a Gaussian solvent-exclusion model. All three
implicit solvent models generate minima that are in good agreement with minima obtained from
simulations with explicit solvent. Moreover, free energy profiles generated with each implicit
solvent model agree with free energy profiles obtained with explicit solvent. For the Gaussian
solvent-exclusion model, we demonstrate that a straightforward ranking of the relative stability
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of each minimum suggests that the most stable structure is extended, a result in excellent
agreement with the free energy profiles. Overall, our data demonstrate that for some peptides
like PHF6, implicit solvent can accurately reproduce the set of local energy minimum arising
from quenched dynamics simulations with explicit solvent. More importantly, all solvent models
predict that PHF6 forms extended P-structures in solution - a finding consistent with the notion
that PHF6 initiates neurofibrillary tangle formation in patients with Alzheimer's disease.
Introduction
An appropriate representation of solvent is critical for obtaining physiologically relevant
results from biomolecular simulations [132-134]. The most straightforward approach for
modeling solvent is to explicitly include solvent molecules in molecular dynamics (MD)
simulations. However molecular simulations with explicit solvent increase the degrees of
freedom in the system and therefore can incur a significant computational cost. Consequently a
number of implicit solvent models have been developed to reduce the computational complexity
associated with solvated simulations. Such models modify the potential energy function to
reproduce the effects of solvation without explicitly representing solvent atoms [132, 133]. As
simulations with implicit solvent models have lead to important insights, these models have
gained widespread acceptance in the field of biomolecular simulations [132]. As evidence of
this, the literature is replete with studies that make conclusions based solely on data obtained
from such models [132]. Recent studies, however, suggest that implicit solvent models can
sometimes lead to results that are at odds with data obtained from explicit solvent simulations
and experimental observations [135-137]. Therefore it is likely that not all implicit solvent
models are appropriate for every application. Moreover, the correct choice of solvent model to
use for any given problem likely depends on the system to be studied, whether qualitative or
quantitative results are desired, and the degree of accuracy required.
In the present study we explore whether conformational sampling with implicit solvent
models can yield results similar to that obtained with explicit solvent simulations. The solvent
models that form the basis of this work include: i) an early implementation of the Generalized
Born (GB) model as described by Brooks and co-workers [138]; ii) an alternate implementation
of the Generalized Born formalism which is based on an integral equation approach and that
employs a simple smooth switching function (GBSW) [139]; iii) the effective energy function-1
(EEFl) implicit solvent model [140]; and iv) the TIP3P model of explicit solvent [141].
The GB model uses a linearized form of Still's equation to estimate the electrostatic
component of the solvation free energy [138, 142]. The equation itself contains six independent
parameters that are varied to optimize agreement between GB solvation energies and solvation
energies calculated with a Finite-Difference-Poisson-Boltzmann (FDPB) algorithm [138]. As the
Born radius is inversely related to the atomic polarization energy, Born radii can be calculated
from the GB energies after parameter fitting [138]. The model has been widely applied and its
utility has been demonstrated in a number of applications [138, 143].
The GBSW model, like the GB model, is based on Still's equation, however, GBSW
employs a more rigorous integral equation approach to calculate the Born radii. In this method,
the electrostatic solvation energy of a given atom is expressed as a sum of two terms - the self-
solvation energy in the Coulombic approximation plus a term which accounts for the reaction
field [139]. Each term is calculated using a surface/volume integration that employs a smooth
switching function at the dielectric boundary to ensure numerical stability during molecular
simulations [139]. Unlike the GB method, the GBSW model contains two adjustable parameters
which dictate the relative importance of the Coulombic field term and the reaction field term
[139]. As before, the values of these parameters were obtained by minimizing the least square
error between GBSW energies and those calculated with a FDPB approach [139]. Once the
optimal values of the adjustable parameters are known, the Born radii can be calculated in a
straightforward manner. The current implementation of the GBSW algorithm also incorporates a
nonpolar contribution to the solvation free energy using the solvent exposed surface area of the
protein of interest, and a user defined surface tension coefficient. The GBSW model has been
used to refine model structures of the C-terminal domain of Hsp33 protein, obtained from sparse
NMR data, into native-like folds which matched solved structures [144]. In addition, GBSW has
been used to examine intermolecular interactions between actin and myosin, leading to new
observations regarding a mutation associated with familial hypertrophic cardiomyopathy [145].
Overall, the model appears to be applicable to a broad range of problems.
The effective energy function-l (EEFl) estimates the solvation free energy using a Gaussian
solvent-exclusion model [140]. EEF1 expresses the solvation free energy of a protein as a sum of
group contributions, where each contribution is equal to a reference solvation energy (i.e., the
solvation energy of the group alone) minus an integral over a solvation free energy density
function. The underlying assumption is that the integral over the free energy density is well
approximated by a sum of Gaussian functions [140]. Important aspect of the model are that
charged side chains are neutralized and a distance dependent dielectric is used to further
attenuate electrostatic interactions. The model has been used in a number of applications and
interesting results have been obtained. Most notably, EEF1 has been used to calculate unfolding
trajectories of proteins [146], discriminate correctly folded from unfolded structures [147], and to
probe the interactions between regions of a-lytic protease (aLP) leading to a better understanding
of the relative importance of different interactions in stabilizing the native state [148].
In the present study we address a specific, well-defined, problem. We determine whether
each of these solvent models can reproduce the set of local energy minima obtained from
quenched MD (QMD) simulations with explicit solvent. To this end we perform QMD
simulations with each of the aforementioned implicit solvent models and compare these results
to those obtained with a TIP3P model of solvent. We note that QMD is a widely used method
for locating local energy minima on a given potential surface. The procedure consists of high
temperature MD simulations (typically at 1000K), followed by minimization of the resulting
structures [149]. High temperature simulations ensure that a wide region of conformational
space is sampled and the subsequent minimizations assure that only local energy minima are
analyzed. Minimization can be performed by coupling the system to a heat bath at OK [150,
151], or by using standard energy minimization algorithms such as steepest descent or conjugate
gradients [152]. QMD has been used to determine optimal positions and orientations of small
functional groups in the binding site of an enzyme [150], estimate the density of states for
proteins [153], and to study the conformational landscape of peptides and peptide analogues
[151, 152].
Our studies focus on a 6-residue peptide commonly referred to as paired-helical filament 6
(PHF6), which corresponds to the sequence found at the N-terminus of the third microtubule-
binding repeat domain of tau protein (306VQIVYK 31 ). Tau protein forms intracellular aggregates
(also known as neurofibrillary tangles) in patients with Alzheimer's disease (AD) and PHF6
corresponds to the minimal region of tau needed for aggregation to occur in vitro [5, 154, 155].
As the formation of intracellular aggregates may be responsible, in part, for neuronal death in
patients with AD, the predominant low energy states of PHF6 are of particular interest [114,
156]. In performing an analysis of PHF6, the goals of this work are not only to evaluate the
ability of several implicit solvent models to reproduce energy minima on a potential surface that
explicitly models solvent, but also to determine the most stable conformations of this peptide.
Methods
Quenched Molecular Dynamics with Explicit Solvent
Quenched molecular dynamics consisted of high temperature MD followed by extensive
minimization of the structures sampled during the trajectory. A polar hydrogen model of the
PHF6 peptide (VQIVYK) was created from the CHARMM19 polar-hydrogen parameter set and
initial coordinates for PHF6 were built using the IC facility, all within CHARMM [157]. Both
the N and C-termini of the peptide were patched using NTERM and CTERM patches, as is
commonly done, resulting in charged termini (i.e., -NH3+ and -COO-). The resulting structure
was solvated with an equilibrated set of TIP3P water molecules, and waters that overlapped with
the peptide or that were outside of a 19A radius were removed. A total of 823 water molecules
were added to the system. A stochastic boundary setup with a solvent sphere of radius 19A was
used for these simulations [158]. The system was minimized, then heated and equilibrated for
I ns at 1000 K. Production dynamics were performed for an additional 10ns at 1000 K. Sampling
at this temperature facilitates a broad exploration of the conformational space. The temperature
was maintained by weakly coupling (tcoup = 5ps) the system to a heat bath using the Berendsen
method [159]. All explicit solvent simulations employed a nonbond interaction cutoff of 17A
electrostatic interactions were shifted to zero between 14A to 16A while a switching function
was used to cutoff van der Waals interactions at 16A. SHAKE was used to hold hydrogen bond
distances close to their equilibrium values and a 2fs time step was used [160].
Structures were chosen from the trajectory every 10ps and subsequently minimized, resulting
in 1000 distinct minimum energy structures. Minimizations were performed on the entire system
consisting of the peptide and all explicit water molecules. In addition, minimizations used the
nonbond specifications outlined above and consisted of 2500 steps of steepest descent followed
by 2500 steps of conjugate gradient minimization. A root-mean-square gradient (GRMS) cutoff
of 0.01kcal/mol/A was set, such that if the system achieved a GRMS below this value during the
minimization protocol, then the minimization was terminated. The procedure for heating,
equilibration, sampling, and minimization was identical for all of the solvent models investigated
in this study.
Quenched Molecular Dynamics in vacuum
Quenched molecular dynamics simulations were performed in vacuum (e= 1). Comparing the
vacuum minima with minima obtained with the different solvent models enabled us to assess the
affects of the solvent models on the structure of the peptide. The nonbond cutoffs and the
minimization protocol were identical to those used in the explicit solvent simulations.
Quenched Molecular Dynamics Simulations with Implicit Solvent
We performed a similar procedure for finding local energy minima on the potential energy
surface of each implicit solvent model described above. One issue that needs to be resolved is
the correct choice of simulation conditions for each implicit solvent model. In general, we rely
on prior data to choose simulation conditions that optimize the chance that each implicit solvent
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simulation would reproduce minima obtained from the explicit solvent simulations. In this
regard, we note that some temperature coupling algorithms may not be appropriate for all
implicit solvent simulations [161]. In explicit solvent simulations with a Berendsen heat bath, the
entire system, consisting of both the solute and the solvent, are coupled to an external heat bath.
Implicit solvent simulations that utilize similar thermostats only couple the peptide to an external
bath as a continuum model is used for solvent. It has been noted that some thermostats which
couple the solute alone to a heat bath may lead to diminished atomic fluctuations, especially
when the peptide itself is tightly coupled [161]. Diminished rms fluctuations would clearly be
disadvantageous for an approach which attempts to map local energy minima on a large potential
surface.
In order to determine whether a Berendsen thermostat with a coupling constant of 5ps would
be appropriate for our studies, we conducted MD simulations of PHF6 with each implicit solvent
model outlined above and compared these data to simulations conducted with explicit solvent
(when both the peptide and solvent are coupled to an external bath). The resulting root-mean-
square (rms) fluctuations were then compared to rms fluctuations arising from the explicit
solvent simulations. For PHF6 the rms fluctuations arising from all of the implicit solvent
simulations are in reasonable agreement with the rms fluctuations from the explicit solvent
simulations (Figure 5). As we are primarily interested in mapping the local energy minima on the
different potential energy surfaces, and not the dynamical properties of PHF6 in different models
of solvent, these data suggest that simulations with a Berendsen thermostat would be appropriate
for our studies.
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Figure 5 RMS fluctuations for 100ps simulation (100ps equilibration, 100ps production dynamics all at 300K)
of PHF6 in different solvent models using a Berendsen heat bath. Simulation parameters, including nonbond
cutoffs, are as listed in Methods. The average rms fluctuation over all atoms is denoted with a red line.
Lastly we note that the precise model for the nonbond interactions for each implicit solvent
model was chosen based on prior data. The goal here was to optimize the chance that each
model would produce data in agreement with the explicit solvent results.
Quenched Molecular Dynamics with GB
Generalized Born simulations utilized the implementation, and Born radii, originally
described by Dominy et al. [138]. As in our previous study [137], no truncation of nonbond
terms was used as this approach yields better results relative to an approach that employs finite
nonbond cutoffs [162].
Quenched Molecular Dynamics with GBSW
GBSW simulations used the implementation previously described by Im et al. with a half
smoothing length of 0.3A, a nonpolar surface tension coefficient of 0.03 kcal/(mol x A2), and a
grid spacing of 1.5A [139]. Nonbond cutoffs were set to 16A using a switching function for both
van der Waals and electrostatic interactions. Of the 1000 structures, the minimization protocol
described above failed for a single structure, which was excluded from the analysis, yielding 999
distinct structures. The singular failed structure was in a non-physical conformation
corresponding to an energy of 1.3 x1011 kcal/mol, while all other structures had energies that
were less than -400 kcal/mol.
Quenched Molecular Dynamics with EEF-1
The EEF-1 implicit solvent model was used as implemented in CHARMM [140, 157]. As the
nonbond cutoff parameters are integral to the model, the previously described nonbond cutoffs
were used here.
Generation of Ramachandran Plots
Ramachandran density surfaces were created from the minima generated from each of the
quenched dynamics simulations. The 9/y values for residues Gln2-Tyr5 were calculated for each
of the 1000 minima (999 for GBSW), and a density function was computed using the
scattercloud function (written by Steve Simon) obtained from the MATLAB central code
repository (http://www.mathworks.com/matlabcentral/). The densities were normalized by their
maximum values and rendered as surface plots using MATLAB. Approximate secondary
structure regions as defined in [1] corresponding to a-helical and P structure are colored.
Generation of Minimum Pairwise Distance (MPD) Plots
Histograms of Minimum Pairwise backbone rms Deviations (MPD) between minima from
different models (a reference model and a comparison model) were computed. These histograms
were used to determine whether each minimum in the reference model was adequately
represented by a structurally similar minimum in the comparison model. For example, suppose
explicit solvent is the reference model and data arising from the EEF1 simulations is the
comparison model. The MPD plot is used to determine if each explicit solvent minimum is
represented in the set of EEF1 minima. For each TIP3P minimum, we find the EEFI minimum
with a backbone conformation closest to the TIP3P minimum in question. This set of rms
deviations provides an objective assessment of how well the EEF1 minima reproduce the
structures corresponding to the explicit solvent minima. It is also of interest to determine the
converse; i.e., whether each EEF 1 minimum is well represented by an explicit solvent minimum.
The converse is computed by setting EEF 1 as the reference model and the explicit solvent results
as the comparison model. If EEF1 generated many spurious minima that did not correspond to
explicit solvent minima, then the resulting histogram of rms deviations would contain many large
values. Therefore, two sets of MPD plots were computed for each of the implicit solvent
models. In one set of calculations the explicit solvent minima formed the reference set and in the
other set of calculations, the implicit solvent model served as the reference. Histograms were
computed using MATLAB and plots of aligned structures were constructed with VMD [163].
Potential of Mean Force Calculations for PHF6
Free-energy profiles for PHF6 were computed for each solvent model. The reaction
coordinate for these simulations was the radius of gyration of the peptide main-chain atoms. The
simulations began by restraining the backbone to adopt an extended conformation with a radius
of gyration of 5.5A using a harmonic constraining potential with a force constant of 25
kcal/mol/A 2. The system was then equilibrated at 300°K for Ins. The potential of mean force
(pmf) for a given solvent model was calculated by running a series of simulations (windows),
where the peptide is restrained to a different radius of gyration using a harmonic force constant
of 25 kcal/mol/A 2. The first window was centered at 5.5A and subsequent windows began with
the final state from the preceding window. The radius of gyration was decreased by 0.1A for
each new window. Restrained molecular dynamics for each window involved 20ps of
equilibration followed by 80ps of production dynamics. Additional dynamics were performed to
extend the pmf boundaries and improve sampling for regions of the pmf that exhibited
discontinuities. Specifically, windows for extended states of the peptide were run at 0.1A
intervals for rgyr constraints ranging between 5.6A and 6.6A to extend the boundaries of the
pmf.
In order to compute the potential of mean force, the radius of gyration was computed every
20fs for each window of dynamics. From these data a biased probability density, pi* is computed
and the potential of mean force, W(), is computed using the relation [158]:
W () = -kBT In p, ( )- V () + C, (3.1)
where kB is Boltzmann's constant, T is the temperature, Vi is the restraining potential for
window i, and C is a constant. In order to construct one continuous potential of mean force, the
different pmfs from each window need to linked together - a process performed by the program
SPLICE [164].
In order to determine that our pmf had converged, we performed additional simulations for
new windows constrained at RGYR that were offset 0.05A from the original window constraints
and determined that this convergence criterion was satisfied. Our metric for convergence of the
pmf was based on the location of the pmf minimum, since this is the primary quantity of interest
for this study. Specifically, we required that the location of the pmf minimum changed by less
than 0.25A as the window step size was halved.
Representative structures from the global energy minimum in each pmf were generated by
first averaging the structures sampled at the window corresponding to the global energy
minimum followed by minimization to the nearest local energy minimum. All molecular figures
were constructed with VMD [163].
Calculating Vibrational Entropies
Vibrational entropies were calculated from the 1000 distinct minima obtained from EEF1
simulations. To ensure that only non-negative eigenvalues would be generated from the normal
mode calculations, each minimum was further minimized using 1000 steps of steepest descent
minimization followed by 2500 steps of adopted-basis Newton Rhapson minimization. The
corresponding Hessian matrix was then diagonalized to yield the normal modes and their
corresponding frequencies. The vibrational entropy for a given minimum was computed as
follows [165, 166]:
-TSb = kT In(1 - e- h, /(kT)) hvi(kT) (3.2)
i=l e
where N is the number of atoms in the system, h is Planck's constant, kB is Boltzmann's
constant, and , -6 are the normal mode frequencies. CHARMM, was used to create the
Hessian matrix from minimized structures and MATLAB (C Mathworks) was used to calculate
vibrational entropies from the Hessian matrix, yielding 1000 vibrational entropy measures; i.e.,
one for each minimum [157].
We note that a harmonic analysis could only be performed on minima arising from the EEF 1
simulations as second derivative calculations with GB are not supported in CHARMMv32a2 and
despite the extensive additional minimization, Hessian matrices for GBSW structures had
negative eigenvalues, thereby preventing a normal mode analysis.
Results
Minimum energy conformations with explicit solvent
Minima on the potential energy surface of PHF6 were obtained from high temperature
molecular dynamics simulations with explicit solvent followed by extensive minimization (i.e.,
quenched dynamics). After 10ns of molecular dynamics at 1000K, a range of conformations was
sampled and subsequent energy minimization yielded 1000 distinct structures corresponding to
different local energy minima. These structures span a range of conformations from the compact,
with a radius of gyration (rgyr) near 3A, to a rgyr of almost 5.6 A (Table 1). By contrast, minima
arising from quenched molecular simulations in vacuum are relatively homogeneous and have
radii of gyration that are distributed over a narrow range - between 3.0A and 3.5A, suggesting
that compact states are overwhelmingly favored in the vacuum simulations (Table 1).
Solvent Model Average rgyr (A) ± std Minimum rgyr (A) Maximum rgyr (A)
TIP3P 4.1 + 0.63 3.0 5.6
Vacuum 3.1 ± 0.06 3.0 3.5
GB 4.7 + 0.46 3.2 5.7
GBSW 4.5 ± 0.55 3.1 5.7
EEF 1 4.7 ± 0.47 3.4 5.9
Table 1: Statistics of minima obtained from quenched molecular dynamics simulations with different solvent
models.
To quantify the diversity among the different minimum energy structures, we computed the
backbone rms deviation between all pairs of minima ( Figure 6). As we are interested in
distinguishing extended structures from compact structures, in addition to secondary structural
motifs sampled by the peptide, we focus on comparisons of the backbone rms deviation between
different pairs of conformers. These data confirm that the explicit solvent minima are
considerably more diverse than minima arising from the vacuum simulations. In particular, the
most extended structure from the vacuum simulations has a radius of gyration of only 3.5 A and
contains a salt bridge between the N and C-termini (Figure 7). In vacuum this salt bridge is
exceptionally stable in that it has an interaction energy near -90kcal/mol and remains intact even
at 1000K. Hence virtually all minima have this salt-bridge and the resulting vacuum structures
are all compact.
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Figure 6: Pairwise distance matrices between minimized structures from the (A) vacuum simulations and
(B) explicit solvent simulations. Each pixel color corresponds to a pairwise backbone RMS distance. The
color scale is shown at the left of the figure.
Figure 7: Structure of the most extended PHF6 minimum arising from the vacuum simulations (rgyr-3.5A).
Minimum energy conformations with implicit solvent
Minima arising from QMD simulations with implicit solvent sample a range of radii of
gyration that is similar to that found in the set of explicit solvent minima (Table 1). A
comparison between representative minima from the different solvent models further illustrates
the close correspondence between the implicit solvent results and the explicit solvent results (
Figure 8); i.e., the backbone conformations of the implicit solvent minima are similar to that
arising from the explicit solvent simulations.
Figure 8: Representative explicit solvent structures (blue) aligned with their closest implicit solvent
structures. The first row depicts the alignment of GB (orche) minima to TIP3P minima; the second row
shows the alignment of GBSW (cyan) minima to TIP3P; and the last row shows the alignment of EEF1(purple) minima to TIP3P minima.
The degree of similarity between the implicit solvent minima and the TIP3P minima was
quantified by computing minimum pairwise distance (MPD) plots. Each MPD plot is a histogram
of the minimum pairwise backbone rms deviations between minima from two different models; a
reference model and a comparison model. For each minimum in the reference model, the closest
minimum in the comparison model is found and used to generate a histogram of rms deviations.
For example, in Figure 9A the TIP3P minima is the reference model and the GB minima is the
comparison model. These data demonstrate that every explicit solvent minimum is within 1.5A
of a GB minimum (Figure 9A).
A also shows an overlay of the explicit solvent minimum that is farthest away from a GB
minimum; even for this worst case, the two minima have very similar backbone conformations.
MPD plots for the other implicit solvent models reveal the same trend; i.e., each explicit solvent
minimum is within 1.3A of a GBSW minimum (Figure 9B) and 1.5A from an EEF1 minimum
(Figure 9C).
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Figure 9: Minimum Pairwise Distance (MPD) plots (see text). The reverse comparison was done;
reference and comparison sets are labeled. In each case, the two
structures having the greatest RMS difference is overlaid. i.e., MPDs were computed with
each implicit solvent minima serving as the reference model and TIP3P serving as the
comparison model (D-F). These data verify that the implicit solvent simulations do not produce
many extraneous minima - that is, each implicit solvent minimum is close to an explicit solvent
minimum.
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A conformational analysis of the TIP3P minima suggests that the four residues in PHF6 with
defined p9/ angles (residues 2-5) preferentially sample regions of conformational space
corresponding to n-structure (FigureGln2 Ile3
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Figure 10: Comparison of normalized p/Ap densities of
minima obtained by quenched molecular dynamics for
residues Gln2-Tyr5. The region corresponding to the P-
structure peak is colored red and the region corresponding
to the alpha-helix peak is colored green. Following the
general secondary structural regions used in i1], the region
of p-sheet conformations consists of T/W angles within the
range of 9p=[- 1 8 00,-4 501 and y'=[4 50,2 2 50] and the region of
a-helix conformations consists of (pq/ angles within the
range of (p=I-1 8 0,00] and y=[-1000 ,450 ].
region of conformational space (Figure
10).
Potential of Mean Force
Calculations
Free energy profiles were calculated for PHF6 in explicit solvent to determine the
predominant conformation of the peptide in solution (Figure 11). The reaction coordinate for
these simulations was the radius of gyration of the peptide. The global free energy minimum of
the peptide in explicit solvent occurs at approximately 5.2A, corresponding to a relatively
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extended conformation of the peptide (Figure 11) - a finding consistent with the 9c/ densities of
explicit solvent minima.
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Figure 11 Potential of mean force plots for the different solvent models analyzed in this study.
The free energy profiles calculated with each of the implicit solvent models are similar to the
pmfs calculated with explicit solvent; i.e., each has a global minimum located between 5A and
5.5A (Figure 11). Average structures from windows corre ponding to the pmf minima confirm
that these low energy structures are relatively extended (Figure 12). In addition, residues 2-5
from the average structure arising from the explicit solvent pmf minimum have p/y angles that
fall within a region of conformational space consistent with Pf-structure. The GBSW average
structure, however, is least similar to the average structure from the explicit solvent pmf
minimum (Figure 12). The backbone rms deviation between the GBSW pmf minimum and the
TIP3P pmf minimum is approximately 2.7A, whereas the GB and EEF1 structures are within 1A
of the TIP3P pmf minimum structure (Figure 12). Hence while all of the implicit solvent models
show qualitative agreement with the explicit solvent pmf, the average structure arising from
EEF1 simulations at the global free energy minimum is most similar to the average structure
obtained from corresponding simulations with explicit solvent.
Figure 12: Representative structures from the simulation windows corresponding to the global free energy
minimum in each pmf. The backbone rms deviation from the TIP3P structure is explicit shown for each of
the implicit solvent structures.
Ranking Minima from the Implicit Solvent Models
Ideally any sampling protocol designed to find low energy states on a potential surface
should not only discover local energy minimum, but it should also deduce which of the resulting
low energy structures are the most stable. In this regard, we note that EEF1 and potentials based
on the generalized born formalism have been shown to correctly identify the most stable protein
conformation from sets consisting of native and misfolded structures [147, 167-169]. Moreover,
a number of these studies suggest that the most stable state can be deduced from static energy
calculations on energy-minimized structures [147, 167, 169]. Given these observations, we
explored whether static energy calculations on the different implicit solvent minima could
provide enough information for identifying the most stable conformation.
A comparison of the relative energies of the different minima is shown in Figure 13. Both
the GB and GBSW minima have a number of low energy states that are within 2kcal/mol of the
lowest energy structure, and all of these conformations are relatively compact with radii of
gyration near 3.5A (Figure 13). By contrast, the set of EEF1 minima contains a prominent
minimum with a radius of gyration of 5.08A, a value close to the global free energy minimum in
the EEF1 and TIP3P free energy profiles (Figure 13). Hence the most stable conformation of
PHF6 can be identified from an analysis of the EEF1 energies alone.
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Figure 13: Relative energies of minima from each implicit solvent simulation. The radii of gyration of the low
energy structures in each solvent model are explicitly shown. The structure of the lowest energy minimum
arising from the EEF1 simulations is explicitly shown.7-0
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arising from the EEF1 simulations is explicitly shown.
We note that methods which identify the most stable conformation of a protein from static
energy evaluations on distinct energy-minimized conformers typically assume that the solute
entropy at each local energy minimum is roughly the same, and therefore can be ignored [168,
170, 171]. Such approximations may be valid for a number of proteins, but it is not clear
whether such a premise is valid for small peptides like PHF6 [170, 171]. While static energy
calculations with EEF1 lead to results that agree with calculated free energy profiles, this does
not necessarily imply that the solute entropy is the same at each minimum. Therefore, to explore
the role that the solute entropy has in determining the relative stability of the PHF6 minima, we
computed the vibrational entropy of each EEF1 minimum within the context of a harmonic
approximation [166]. The relative free energy of each minimum was then estimated using the
sum of the internal energy (i.e., the EEF1 energy) and the vibrational entropy (Table 2). Ranking
the EEF1 minima using this new measure leads to conclusions that are identical to what was
obtained from an analysis of the EEF1 energies alone. In particlar, the lowest energy
conformations are extended, and the lowest energy structure is the same (Table 2). However, as
is clear from Table 2, the vibrational entropy spans a range of more than 10kcal/mol, a somewhat
larger range than was noted in prior studies on proteins [168, 169]. Including the vibrational
entropy also leads to a change in the ranking of the PHF6 minma. Consequently, even though
our results are similar to those seen when the vibrational entropy is explicitly included, it is clear
that it can play a role in determining the relative ordering of different minima.
Ranking rgyr E (kcal/mol) -TSvib A = E - TSib
(A) (kcal/mol) (kcal/mol)
1 5.08 -191.93 -23.22 -215.15
2 4.90 -177.75 -33.31 -211.06
3 5.16 -185.81 -24.92 -210.73
4 5.03 -186.17 -24.53 -210.70
5 5.10 -185.98 -23.82 -209.80
15 5.04 -186.03 -22.63 -208.66
38 5.01 -177.09 -30.60 -207.69
64 4.45 -185.74 -20.99 -206.73
141 4.46 -172.93 -32.45 -205.37
843 3.99 -175.72 -20.53 -196.25
Table 2: EEF1Nibrational energies of selected EEF1 minima. Minima are ranked in order of increasing
energy.
Discussion
Given their considerable computational efficiency, a number of problems can be approached
with the aid of implicit solvent models that would be intractable if only explicit solvent models
were available [143-148, 167]. However not all implicit solvent models are created equal, and
some may be more appropriate for particular problems. As such, studies such as the present
work, which aim to delineate the limitations as well as the advantages of different implicit
solvent models, may help to decide which model to use for any given application.
This study was designed to address a specific question - namely, could selected implicit
solvent models adequately reproduce the set of local energy minima found on a potential surface
that explicitly includes solvent. Towards this end, we mapped local energy minima on different
potential surfaces and compared these minima to minima obtained from simulations with explicit
solvent. We found that GB, GBSW, and EEF1 performed quite admirably in that they were able
to successfully reproduce the set of minima obtained from explicit solvent simulations.
Ramachandran plots of the resulting structures confirm that all solvent models sampled similar
regions of conformational space. Furthermore, free energy profiles obtained from all three
implicit solvent models were in good agreement with free energy profiles obtained with explicit
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simulations employed an infinite cutoff because it has been shown that this cutoff scheme yields
results that are in good agreement with explicit solvent for some systems [162]. The GBSW
simulations used a finite nonbond cutoff of 16A because this value leads to reasonable
computation times with relatively small errors in the calculated forces [139]. Nevertheless, a
16A cutoff for a small peptide like PHF6, leads to almost no truncation of the nonbond terms.
As a result, the nonbond lists for the GB and GBSW simulations are quite similar. The longer
simulation time for GBSW is due to the fact that, unlike GB, GBSW employs a relatively
expensive surface/volume integration to calculate the electrostatic contribution to the solvation
energy [138, 139].
In order to determine whether the most stable state of PHF6 could be identified from an
analysis of the minima alone without additional umbrella sampling, we examined the relative
energies of minima arising from each implicit solvent simulation. The lowest energy structure
from the set of EEF1 minima is extended and has a radius of gyration near that found in the free
energy profiles. By contrast, the lowest energy structures from the GB and GBSW simulations
are relatively compact. Hence, for PHF6, one could correctly deduce that extended structures are
most stable from an analysis of the EEFI energies alone. These data are encouraging as they
suggest that an analysis of minima obtained from simulations with EEF1 may provide insights
that are comparable to what one would obtain from umbrella sampling calculations with explicit
solvent - a considerably more taxing approach.
It should be noted that this conclusion may not be generally applicable. Ranking EEF1
minima based solely on static EEF1 energies assumes that the solute entropy at each minimum
can be safely ignored. However, estimates of the vibrational entropy reveal that the solute
entropy can vary significantly at each minimum. Although our conclusions are the same when
the vibrational entropy of each minimum is explicitly calculated, the ranking of the EEF1
minima is somewhat altered when this is done. Therefore we cannot rule out that estimates of
the solute entropy are needed to accurately identify the most stable conformation of other
peptides. In this regard, we note that static energy evaluations of GB and GBSW minima lead to
conclusions that differ from that obtained from the pmf calculations in explicit solvent. As
normal mode analyses could not be performed on GB and GBSW minima, it may be that more
accurate results could be obtained if a vibrational analysis were performed on these minima.
In our previous study we found that both EEF1 and GB were unable to reproduce the free
energy profile obtained from simulations with explicit solvent using a different peptide system
[137]. In that work we umbrella sampling calculations with explicit solvent to calculate this
peptide's potential of mean force as a function of its radius of gyration [137]. The FRET
efficiency for this peptide, which was calculated from the pmf, was in excellent agreement with
experiment. Central to the success of the explicit solvent simulations was the formation of a
stable salt bridge between glutamate 5 and arginine 11. By contrast, in both the GB and EEF1
simulations, the formation of a glutamate-arginine salt bridge was unfavorable, and consequently
simulations with these implicit solvent models lead to calculated FRET efficiencies that
disagreed with the explicit solvent results [137]. While the solvation energy of individual side
chains is likely well modeled by these implicit solvation models, it is not clear that energetics of
salt-bridge formation is appropriately modeled by these approaches [137, 172]. This may be
particularly true for salt-bridges which involve arginine residues [172]. As such, the absence of
multiple charged side chains in the sequence of PHF6 likely explains the difference between the
present results and those of our prior work. For PHF6, representative structures from the lowest
energy state within the explicit solvent pmf contain one salt-bridge between the side chain of
lysine 6 and the C-terminal carboxyl of the same residue (Figure 12). Therefore the explicit
solvent pmf suggests that the lowest energy state is extended without any salt-bridges or
hydrogen bonds between moieties that are separated in the sequence. This simple extended state
which lacks salt-bridges or hydrogen bonds between distant residues is well modeled by the
implicit solvent models investigated in this work.
All of the solvent models predict that PHF6 preferentially adopts extended structures in
solution, and a conformational analysis of amino-acids in PHF6 argues that residues 2-5 adopt
9/y values corresponding to the P-strands. These findings have important implications for the
pathogenesis of neurofibrillary tangle formation in patients with Alzheimer's disease. In
particular, there is growing consensus that the ability of amyloidogenic proteins like tau to
aggregate stems from properties of the protein backbone. In many instances, protein aggregation
requires the formation of intermolecular backbone hydrogen bonds yielding a cross 3-structure
(i.e. the p strands are perpendicular to the axis of the fibril), and for tau this process is likely
important for the initiation of neurofibrillary tangle formation ([173-175]).
Our findings imply that PHF6 exhibits a strong preference for extended p-structures in
solution - a finding which suggests that PHF6 promotes neurofibrillary tangle formation by
facilitating the formation of cross p-structure between tau monomers. This premise is consistent
with recent data suggesting that the sequence of PHF6 is the minimal region of tau required for
tau aggregation into cross-p filaments and hence neurofibrillary tangles [5]. As neurofibrillary
tangle formation may play a role in neurodegeneration [114], therapies directed at modifying the
structural preference for PHF6 may lead to new treatments for dementias like AD and the
tauopathies [176].
Chapter 4: The Effect of a AK280
Mutation on the Unfolded State of a
Microtubule-Binding Repeat in Tau
(This work was published as A. Huang and C. M. Stultz, "The Effect of a AK280 Mutation on the Unfolded
State of a Microtubule Binding Repeat in Tau," PLoS Computational Biology, vol. 4(8): e1000155, pp. 1-
12, 2008.)
Abstract
Tau is a natively unfolded protein that forms intracellular aggregates in the brains of patients
with Alzheimer's disease. To decipher the mechanism underlying the formation of tau
aggregates, we developed a novel approach for constructing models of natively unfolded
proteins. The method, Energy-minima Mapping and Weighting (EMW), samples local energy
minima of subsequences within a natively unfolded protein and then constructs ensembles from
these energetically favorable conformations that are consistent with a given set of experimental
data. A unique feature of the method is that it does not strive to generate a single ensemble that
represents the unfolded state. Instead we construct a number of candidate ensembles, each of
which agrees with a given set of experimental constraints, and focus our analysis on local
structural features that are present in all of the independently generated ensembles. Using EMW
we generated ensembles that are consistent with chemical shift measurements obtained on tau
constructs. Thirty models were constructed for the second microtubule binding repeat (MTBR2)
in wild-type (WT) tau and a AK280 mutant, which is found in some forms of frontotemporal
dementia. By focusing on structural features that are preserved across all ensembles, we find
that the aggregation-initiating sequence, PHF6*, prefers an extended conformation in both the
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WT and AK280 sequences. However, in WT MTBR2 the region immediately downstream from
PHF6* can adopt a loop/turn conformation while the corresponding region in the AK280 mutant
only exhibits a conformational preference for extended conformations. As an increased
preference for extended states near the C-terminus of PHF6* may facilitate the propagation of 3-
structure downstream from PHF6*, these results explain how a deletion at position 280 can
promote the formation of tau aggregates.
Introduction
Alzheimer's Disease (AD) pathology is characterized by extracellular aggregates of A3-
amyloid (AP) and intraneuronal tau aggregates, known as senile plaques and neurofibrillary
tangles (NFTs), respectively [177]. Despite much focus on AP amyloid in AD research, tau
seems to play an important role as well. For example, the number of NFTs and not the number
of senile plaques in the neocortex correlates with the severity of dementia in AD patients, and
there are data that imply that abnormalities in tau alone may cause neurodegeneration [12]. In
light of these observations, a detailed characterization of the structure of tau protein may provide
insights into the pathogenesis of AD and other neurodegenerative disorders associated with tau
pathology. However, probing the structure of tau is difficult because tau protein is natively
unfolded (or intrinsically disordered) in solution. Several studies suggest that tau retains its
function after heat or acid-induced denaturation and both CD and x-ray scattering experiments
imply that tau does not adopt a well-defined folded structure in solution [55, 178, 179].
Consequently, obtaining structural and hence functional information on tau is problematic
because the direct observation of unfolded states is typically difficult to achieve experimentally.
Initially, unfolded proteins were described as random coils whose properties are derived from
Flory's statistical description of chain molecules [43]. For such polymers, the radius of gyration,
RG, follows the scaling law &R = R0N", where Ro is the radius of gyration of a monomeric subunit
(a function of the persistence length), N is the number of subunits in the polymer, and v is a
scaling factor that depends on the solvent characteristics. The most common measure of whether
a protein behaves as a random coil is to test whether its radius of gyration follows this scaling
law. However, while a structurally disordered molecule can exhibit random coil statistics, the
converse is not necessarily true; i.e., random coil statistics do not imply that the structure is
completely disordered [180]. Slight structural preferences may exist for some natively unfolded
proteins and small changes in the distribution of conformers within an unfolded ensemble may
play a role in the normal and pathological functioning of intrinsically disordered systems. A
recent study, for example, suggests that inducer-mediated tau polymerization involves an
allosterically regulated conformational change [181]. This is consistent with the notion that the
formation of tau fibrils is associated with a shift in the conformational distribution of tau such
that the unfolded state has a preference for pro-aggregatory conformations in the presence of an
inducer. In light of this, constructing detailed ensembles that model the unfolded ensemble of
tau may facilitate the identification of structural properties that promote aggregation.
As full-length tau contains more than 400 amino-acids (441 residues for the htau40 isoform
[112]) constructing detailed ensembles that model the unfolded state of this protein is a daunting
task. Fortunately, tau contains three or four imperfect microtubule-binding repeats (MTBRs)
near the C-terminus of the protein and almost all known mutations of tau that are associated with
inherited forms of neurodegenerative-diseases, are located in MTBR domains or their nearby
flanking regions [182]. As these data suggest that MTBRs play an important role in the
progression of inherited tauopathies, we first focus on building ensembles that model the
structure of individual MTBRs. It is important to note, however, that we do not strive to model
the structure of a given MTBR fragment alone in solution. Rather, our goal is to generate
ensembles that model the range of conformations that a MTBR can adopt when it is part of full
length tau. In the present study we focus on building ensembles for the second MTBR,
henceforth referred to as MTBR2. This repeat is of particular interest because it contains both a
six amino-acid repeat, PHF6*, which is a minimum interaction motif that can initiate tau
aggregation in vitro [154, 155], and the site of the pro-aggregatory mutation, AK280, which is
associated with some forms of frontotemporal dementia [6, 7, 183, 184].
We have developed a method, called Energy-minima Mapping and Weighting (EMW), to
construct ensembles that model the unfolded state of proteins. The underlying assumption that
forms the basis of this approach is that the unfolded state can be modeled as a set of energetically
favorable conformers, where each conformer corresponds to a local energy minimum. The
method involves constructing a library of energetically favorable conformations and selecting
conformations from this library to form ensembles that are consistent with a given set of
experimental data. We use EMW to build ensembles for wild-type (WT) MTBR2 and the
corresponding AK280 mutant. By comparing data from the two sets of ensembles, we deduce
structural preferences in the AK280 ensemble that explain its increased propensity to form tau
aggregates.
Results
The EMW method begins by constructing sets of energetically favorable conformations for a
sequence of amino-acids within a natively unfolded protein (Figure 15). In the case of tau we
focus on MTBR2 since this region contains the aggregation-initiating sequence PHF6* as well as
the site of a mutation that is associated with increased tau aggregation in vitro [124]. A set of
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Figure 15: Outline of EMW method. The
subsequence chosen for simulations is colored blue
and contains an aggregation initiating sequence
(colored yellow). A set of local energy minima can be
enumerated using quenched molecular dynamics.
Chemical shifts are calculated for the candidate
ensemble and compared to chemical shifts obtained
on the entire sequence. Weights of ensemble members
are modified to improve agreement with experiment.
Sa (j) denotes the chemical shift of the Ca atom in
the jth residue of the ith structure of the ensemble.
S (j) is computed from the th structure using
SHIFTX [2]. SC (j) is the statistical mechanical
equivalent of the experimentally observed chemical
shift of the Ca atom in the jth residue. We note that
although the aggregation-initiating sequence is shown
at the center of the chosen subsequence, this need not
be the case. For MTBR2, the aggregation-initiating
sequence is located at the N-terminus.
local energy minima is then constructed for this
subsequence, hence forming the candidate
ensemble (Figure 15). Associated with each
structure in this ensemble is a weight, o , which
corresponds to the probability that the given
subsequence adopts the ith conformation in the
candidate ensemble. We say that an ensemble
is fully specified when the local energy minima
and weights are known.
Initial weights for structures in the candidate
ensemble are calculated from the relative
energies of each structure, as shown in Figure
15. However, as sampling is performed on a
relatively small subsequence these weights may
not reflect the relative probabilities of different
conformations when the subsequence is part of
the larger protein. For example, compact states
may be preferred over extended states when the
subsequence is in isolation but not when part of
tau. Therefore, the composition of the ensemble is optimized and the members of the candidate
ensemble are re-weighted in light of experimental data that is obtained on a larger segment of tau
protein. Sampling small subsequences increases the chance that we will observe a relatively
large number of accessible states for this system. Using experimental data obtained on a larger
region of tau (and not just the subsequence of interest) helps to ensure that the calculated
ensemble represents the local structure of the sequence as it appears within full length tau.
A central component of EMW is that we do not strive to construct a single model for the
unfolded state. We recognize that the construction of unfolded ensembles that agree with any
given set of experimental data is largely an underdetermined problem; hence it is likely that there
are a number of different ensembles that are consistent with a given set of experimental data.
Consequently, we constructed several ensembles that are all consistent with the experimental
measurements and focused our analysis on local structural motifs that are present in all
ensembles. For this study, we focused on NMR data that are available for both WT MTBR2 and
a AK280 mutant. These data were kindly provided by Marco Mukrasch, Daniela Fischer, and
Markus Zweckstetter [123, 124].
Using the EMW method, 100 ensembles were constructed for both wild-type (WT) and
AK280 sequences of MTBR2 (a total of 200 ensembles). Each ensemble was constructed to
minimize the difference between calculated 13 Ca chemical shifts and the corresponding
experimentally determined 13Ca chemical shifts. The number of structures in each ensemble
corresponds to the minimal number of structures needed to fit the available chemical shifts.
Preliminary calculations found that 15 conformers were needed; i.e., fewer structures resulted in
worse fits to the 13Ca chemical shifts and more structures did not significantly improve the
quality of fits. We note that other models examining residual structure in the unfolded state have
utilized a similar number of representative conformers [57].
Application of EMW yielded ensembles that were in excellent agreement with
experimentally determined absolute 13Ca chemical shifts (Figure 16A & B). The average rms
error between the calculated '3Ca chemical shifts and the corresponding experimental values was
0.1 ppm - well below the error associated with SHIFTX chemical shift predictions and similar to
the error associated with experimental chemical shift measurements on K18 constructs [2, 124].
However, given that measured absolute chemical shifts for the 20 amino acids vary significantly
according to the amino-acid type, reasonable correlations to absolute chemical shifts may be
achieved by simply predicting amino-acid specific random coil values. Given this, we analyzed
the relationship between the chemical shifts, after subtracting out residue-specific random coil
chemical shift values; i.e., the secondary chemical shifts. Overall, there is excellent agreement
between calculated secondary chemical shifts and the corresponding experimental values for
each residue in the sequence (Figure 16C & D). These data demonstrate that the calculated
models yield agreement with experiment on a per residue basis.
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Figure 16: Model vs. experimental absolute Ca chemical shifts for A) 100 WT ensembles and B) 100 AK280
ensembles. Ca secondary chemical shifts (ACa) are also shown for the C) WT and D) AK280 sequences using
the ensemble that had the worst agreement with experiment. The worst model is defined as the ensemble that
has the greatest rms deviation between the calculated and experimentally determined values.
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Table 3: RMS deviation between calculated and experimental CO and H chemical shifts
In the next step of our protocol, carbonyl carbon (13CO) chemical shifts were used to test
whether the resulting ensembles can predict experimental observations that were not used to
construct the model. This helps to ensure that our models are not "overly-fit" to the 13Ca
chemical shifts. In general, a model that is over-fit to a given set of experimental data can
reproduce that data remarkably well, but cannot reproduce data that was not used to generate the
model. Therefore we consider an ensemble to be validated if new experimental results can be
Ensemble WT AK280
accurately predicted from the ensemble. For both the WT and AK280 sequences, each of the 100
ensembles was ranked based on its ability to predict 13CO chemical shifts. Based on these data
the thirty best ensembles were chosen for further analysis. The rms difference between the
calculated 13CO chemical shifts and the corresponding experimental values are below 0.9ppm;
i.e., below the error associated with available chemical shift prediction algorithms (
Table 3) [2]. To further demonstrate that these thirty ensembles can reproduce additional
data not used in the model constructed, we computed the error between calculated amide
hydrogen (IHN) chemical shifts and the corresponding experimental values. The resulting
values agreed with the experimentally measured ones to within 0.3ppm (
Table 3).
As expected, structures that comprise the WT (Figure 17A) and AK280 (Figure 17B)
ensembles are heterogeneous in that they sample a
lure 17: A) An alignment of structures from A) all 30 WT
;embles. B) all 30 AK280 ensembles.
wide range of conformations. Since each of the thirty
ensembles represents an independent representation of the unfolded state, we searched for local
structural motifs that are found in all of the ensembles. More precisely, the existence of a local
conformation that is consistently adopted by a given subsequence in MTBR2 suggests that this
conformation is needed to reproduce the experimental results. We therefore consider conserved
motifs to represent local conformational preferences.
Human Tau, long isoform (441 residues)
MBR1 MBR2 MBR3 MBR4
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AK280 VQIIN -KLDL SNVQS KCGSK DNIKH VPGGG S
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Figure 18: Sequences of WT and AK280
region is underlined in red.
VQIINKKLDLSNVQSKCGSKDNIKHVPGGGS
,Choose a subsequence of interest.
Calculate pairwise RMSD for the local
conformation in all structures from all
ensembles
Clusters local
structures based
on conformational
similarity
forms of the second microtubule-binding repeat in tau. The PHF6*
We begin with an assessment of the local
conformation of PHF6* in both the WT and AK280
ensembles. Since PHF6* in the WT sequence spans
residues 275-280, the AK280 mutant sequence has a
deletion in the six-residue stretch corresponding to
PHF6*. However, since residue 281 is also a lysine, the
AK280 mutant contains an equivalent PHF6*
El subsequence at its N-terminus (Figure 18). This allows us
Find clusters
E2 ............. that are to directly compare the conformation of PHF6* in bothrepresented in
E3 -- -- all ensembles
E4: bq-
Figure 19: Outline of the method used for clustering local conformations. First, a six-residue local region is
selected for analysis. Clusters of structures with similar conformations in the region of interest are formed
based on pairwise RMSDs for backbone atoms in the local region. E-E5 represent different ensembles.
Clusters that are present in all model ensembles are circled in red, while unpreserved clusters are circled
in green.
sequences. To identify preserved conf ormations of PHF6*, we first determined the different
types of structures that this subsequence can adopt by clustering structures using only the
backbone atoms of PHF6* (Figure 19). The probability that a given cluster occurs in an
ensemble is equal to the sum of the weights of structures in that ensemble that contains a motif in
the cluster. Preserved structural motifs are defined as clusters that have a non-zero weight in
every ensemble (Figure 19); i.e., a preserved motif is found in all ensembles. For comparison,
we repeated this procedure for all contiguous six-residue subsequences within MTBR2, yielding
a collection of approximately 300 clusters that represent all possible structural motifs in our
ensembles that any six-residue sequence in MTBR2 can adopt. Using the criterion outlined
above, roughly 5% of these clusters were preserved across all ensembles.
72
A. 275VQIINK280
C. 27 5VQIIN-K 28 1  D.
Figure 20: Structures of the cluster representing the local conformation of PHF6* that is preserved in all
ensembles. A) Aligned structures for WT tau and B) Average backbone conformation for this cluster; C)
Aligned structures for WT the AK280 mutant and D) Corresponding average structure. The backbone of
PHF6* is shown in yellow for the average structures.
In WT MTBR2, clustering based on the conformation of PHF6* yielded 12 distinct
conformations. However, only one of these states was present in all 30 ensembles (Figure 20A,
B). Similarly, while PHF6* clusters into 11 distinct conformations in the mutant AK280
ensembles, only one conformation was preserved (Figure 20C & D). In both cases, the preserved
conformation of PHF6* is extended conformation and has has (p, x~ angles that fall within the
broad region of the Ramachandran plot corresponding to p-structure. This observation is
consistent with the notion that PHF6* a priori adopts extended conformations that can readily
form cross p-structure with other tau monomers [48]. Since the formation of cross p-structure is
believed to play an essential role in the formation of protein aggregates, these data are consistent
with the notion that PHF6* promotes aggregation by forming p-structure between tau monomers
[154, 155].
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Figure 21: Preserved structures for the region corresponding to 278INKKLD283 in both the WT (A-D) and
278IN-KLDL 28 4 AK280 ensembles (E, F). A,C) Aligned structures corresponding to a preserved cluster in the
WT ensembles aligned by backbone atoms of residues of 27 INKKLD 83and B,D) the corresponding average
structures. E) Aligned structures of the preserved cluster in AK280 ensembles, aligned by backbone atoms of
residues 278IN-KLDL 28 4. F) The average conformation of the preserved cluster in AK280 ensembles. In the
average structures, residues belonging to PHF6* are in yellow.
To explore the effect of the AK280 mutation on the local structure of MTBR2, we analyzed
the structure of the subsequences 278INKKLD 283 and 278IN-KLDL 284 in the WT and AK280
sequences, respectively. For WT MTBR2, two conformations for 278INKKLD 283 were found in
all ensembles. The first is a loop/turn that is associated with a change in the direction of the
mainchain (Figure 21A, B). In this structure residue K280 has p, y angles of approximately -102
and -30, respectively; i.e., mainchain dihedral angles consistent with an a-helical/turn
conformation. The second conformation is more extended, having p, y angles that place its
residues within the broad region corresponding to extended f3-structure (Figure 21C, D). In the
mutant sequence, residue K280 is absent and the corresponding sequence, 278IN-KLDL 283, has
one preserved conformation. The deletion of residue 280, which can adopt an a-helical/turn
conformation in the native sequence, results in the local region preferentially adopting an
extended conformation (Figure 21E, F). The deletion, however, also introduces a slight kink in
the mainchain of the sequence (Figure 21F).
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Figure 22: Preserved structures for the region corresponding to residues 2 82LDLSNV2 87 in both the WT (A-D)
and AK280 ensembles (E, F). A,C) Aligned structures corresponding to a preserved cluster in the WT
ensembles aligned by backbone atoms of residues of 282LDLSNV287 and B,D) the corresponding average
structures. E) Aligned structures of the preserved cluster in AK280 ensembles, aligned by backbone atoms of
residues 282LDLSNV28 7. F) The average conformation of the preserved cluster in AK280 ensembles. The
location of S285 in the bend is indicated in red in the average structures.
In a prior work, N-H residual dipolar coupling (RDC) values were measured for residues in
the WT K18 construct in polyacrylamide gel [19]. While most residues in MTBR2 have
relatively large negative RDC values, S285 has a large positive value [19]. This difference can
be explained by either a change in the local alignment tensor at S285, or the presence of a-
helical/turn structure at this site [60, 185-187]. Accelerated molecular dynamics simulations of
WT K18, however, confirm that the sequence 283DLSN 286 samples turn conformations with
relatively high frequency [19]. In light of these observations, we explored the structure of the six
residue segment, 2 82 LDLSNV28 7, that includes residue S285. This region adopts two
conformations that are preserved across all WT ensembles. One of the conformations contains a
loop/turn (Figure 22A, B) where residue S285 has 9, W angles of -63, -39 respectively; i.e., near
the optimal a-helical values (Figure 22B). The alternate conformation is extended and does not
result in a change in the direction of the mainchain (Figure 22C, D). However, in the AK280
mutant, 282LDLSNV287 has one structure that is preserved across all ensembles (Figure 22E, F).
In this structure S285 again adopts 9, y angles (-95 and -63, respectively) that are consistent with
an a-helical/turn conformation (Figure 22F). These data agree with the RDC data mentioned
above and suggest that this region in both the WT and mutant sequences is able to adopt turn-like
conformations in solution as well as in a polyacrylamide gel.
Discussion
Dynamical simulations provide a valuable tool for the analysis of unfolded proteins,
providing insights that would be difficult to obtain from experiments alone [76]. A number of
simulation methods have been developed to model the unfolded states of proteins and useful
insights have been obtained with these techniques. Many of these approaches generate
ensembles by directly incorporating experimental constraints into molecular dynamics
simulations in order to facilitate conformational sampling. These methods bias molecular
trajectories to sample conformers that are consistent with a given set of experimental data. One
problematic issue with biased sampling, however, is that it can suffer from over-fitting - a
process which may yield a distribution of conformers that do not accurately model the range of
structures that comprise the unfolded state [76]. Given this concern, a number of unbiased
methods have been developed to generate ensembles for unfolded proteins. These approaches
utilize fast algorithms, which do not employ a physical potential energy function, to obtain
representative structures of the unfolded state, and in some cases experimental data can then be
used to improve the resulting ensembles [68, 77, 188, 189]. The algorithm ENSEMBLE, for
example, adjusts population weights for pre-generated conformers to improve agreement with
experimental data in a manner similar to that described here [77].
A unique feature of the present method is that it does not strive to generate a single ensemble
that represents the unfolded state. Given that accurate modeling of an unfolded protein is an
undetermined problem, it is likely that there are a number of different ensembles that agree with
any given set of experimental data. Moreover, given the immense number of potential
conformations that an unfolded protein can adopt, this may be true even when a relatively large
number of experimental constraints are used to construct the ensemble. Hence our goal was to
construct several candidate ensembles, each of which agrees with a given set of experimental
constraints, and focus our analysis on local structural features that are preserved across all
ensembles. Local structural features that are found in all independent ensembles likely represent
motifs that are required to reproduce the experimental data. In other words, given the
underdetermined nature of the problem, it is not clear how to determine when one has the
"correct" ensemble. However, local structural motifs that consistently appear in all independent
ensembles are likely to also be present in the "correct" ensemble. Consequently, we consider
locally preserved structural motifs to represent local conformational preferences.
An important consideration in our method is the choice of experimental data that is used to
build and validate the constructed ensembles. In principle, EMW can use any set of
experimental measurements to optimize and validate model ensembles. Indeed, as more
structural information is made available, additional data can and should be used to further refine
the set of model ensembles. In this regard, we note that although a number of NMR
measurements have been made on native tau constructs, the data available for constructs
containing a AK280 mutation is relatively limited. In a prior study, nuclear chemical shifts and
HSQC spectra were measured for the K18AK280 construct, which contains all four MTBRs and
the AK280 mutation [124]. Data were obtained for both free K18AK280 and for K18AK280 in
the presence of the polyanion heparin and microtubules [124]. However, as we are interested in
building structural models for MTBR2 in solutions free of compounds that promote tau self-
association (e.g., heparin) and free of proteins known to bind tau, we focused on measurements
obtained with the free K18AK280 construct. Additionally, as there are a number of existing
methods that relate chemical shift measurements to three dimensional protein structures [2, 190-
192] we considered 13Ca, 13CO, 1HN and 15N chemical shift measurements; i.e., the only
available chemical shifts for K18AK280 [124]. Futhermore, established methods for estimating
NMR chemical shifts can predict carbon and amide proton chemical shifts with an error of
approximately lppm or less, while the error associated with predicting nitrogen chemical shifts is
substantially larger (~2-2.5ppm) [2, 191-193]. Therefore we focused on the 13 Ca, '3 CO and 'H
chemical shifts for this study because these data represent measurements that can be calculated
with the greatest accuracy and that are available for both native tau constructs and the AK280
mutant.
It has long been recognized that chemical shifts of a given residue are, in general, largely a
function of the local environment of the residue in question [194, 195]. Since we generate
ensembles that agree with chemical shifts, a limitation of the results reported here is that we do
not explicitly include experimental data that more directly reveals information about non-local
interactions. While long range contacts have been identified in some natively unfolded proteins
(e.g., [57]), the dimensional scaling characteristics of intrinsically disordered proteins suggests
that stable long-range contacts are sparse in these systems [196]. Nevertheless, we suggest that
the combination of a physical potential energy function, which can in principle model long range
interactions, and experimentally determined chemical shifts can provide insight into the structure
of proteins in general. In this regard we note that data are emerging which suggest that backbone
chemical shifts, when used in conjunction with a physical energy function, may be sufficient to
adequately predict tertiary folds, and consequently stable non-local contacts, for some proteins
[197, 198].
Although our work focuses on the structure of the MTBR2 without explicitly including other
MTBRs, our findings may also have implications for full length tau. Once a representative set of
conformers for MTBR2 is generated, we strive to ensure that the calculated chemical shifts agree
with chemical shifts obtained using a construct that contains all MTBRs. This helps to guarantee
that the ensemble models the structure of MTBR2 as it appears in full length tau. In short, we
are not interested in the structure of MTR2 as it appears alone in solution; instead we hope to
deduce structural features of MTBR2 as it appears in full length tau. In addition, as MTBR2
contains an aggregation-initiating sequence that is known promote tau aggregation in vitro as
well as the site of a mutation that leads to in increased tau aggregation in vitro and in vivo,
studies of both its WT and mutant forms may lead to insights into the mechanism of tau
aggregation [6, 155, 199].
The ability to form intermolecular -sheet conformations appears to be a relatively general
property of polypeptide chains that are associated with disorders of protein misfolding and
aggregation [36, 173, 200, 201]. Therefore it is likely that an inherent propensity to form
extended conformations, that are consistent with p-structure, will promote aggregation in
natively unfolded systems. When EMW is applied to MTBR2, we find that the aggregation-
initiating sequence, PHF6*, adopts an extended conformation in both the WT and AK280
ensembles, a finding consistent with the observation that these peptides can initiate tau
aggregation [154, 155]. Interestingly, in a prior work we demonstrated that a related
hexapeptide, PHF6, preferentially adopts an extended state that can facilitate the formation of
cross- 3-structure between tau monomers [48]. The present study suggests that this property is
preserved when aggregation-initiating sequences are part of their corresponding MTBRs. That
is, PHF6* a priori adopts extended conformations that can readily form hydrogen-bonded 3-
structure. Additionally, a recent survey of amyloidogenic proteins suggests that fibrillogenesis
for natively unfolded proteins involve the formation of partially folded intermediates that can
subsequently go on to form amyloid fibrils [36]. Our findings are consistent with these
observations in that our results imply that formation of a locally stable, and extended,
conformation plays a role in the formation of tau aggregates.
Recently, several studies have attempted to characterize residual structure of MTBRs in tau
[19, 122-124, 202, 203]. These studies can be roughly divided into two categories: descriptions
of ensemble average characteristics based on NMR measurements [19, 122-124], and NMR
solution structures of local regions obtained by adding organic solvents to stabilize a unique fold
[202, 203]. Since the presence of organic solvents leads to significant changes in the
conformational distribution of states, as evidenced by the dramatic changes in the CD spectra
[55, 202, 203], the physiologic relevance of these latter results remains unclear. However, early
characterizations of MTBRs in non-organic solvents, found that the PHF6 region likely has a
higher propensity for extended, P-strand like conformations - a finding in accord with our data
[122, 123].
Given that both WT and AK280 tau contain aggregation-initiating sequences (Figure 18), it is
not clear how P-strand propensity in this region explains the difference in aggregation potential
between the two sequences. Therefore to deduce structural features of the AK280 mutant that
explain its proclivity to form aggregates, we analyzed the structure of MTBR2 in the vicinity of
the mutation site. Unfolded ensembles of WT MTBR2 contain two conformations at the
mutation site that were present in all ensembles - a loop/turn conformation and an extended
state. In contrast to the WT MTBR2 ensembles, models of AK280 in the same region had one
conformation that was present in all ensembles. This state is relatively extended and contains a
kink at the site of the deletion. While the slight disruption in the extended state of the mutant
may also influence the ability to form hydrogen-bonded cross-p structure, a loop/turn at the C-
terminus constitutes a much greater impediment to the formation of P-structure. Since residue
K280 has a relative preference for non-extended states, deletion of this residue leads to increased
sampling of extended states downstream from PHF6*. The relative preference for extended
structures downstream from PHF6* in the AK280 mutant suggests that the ability to propagate P-
structure distal to PHF6* can affect the aggregation potential of tau. These observations
therefore explain how the deletion of a single residue can change the aggregation potential of tau.
We also find that in both WT and mutant ensembles residue S285 can adopt p, y angles
consistent with an a-helical/turn structure. Recent data on the WT sequence are also consistent
with these observations as RDC values and molecular dynamics simulations suggest that S285
adopts an a-helical/turn structure. Since those experiments were preformed in polyacrylamide
gel, our data suggest that this structure also occurs with relatively high frequency in solution. It
is also worthwhile to note that although we find that a six-residue region including K280 can
adopt a similar loop/turn conformation, the associated RDCs for this region are not associated
with a change in sign, like that observed at S285 [27]. Nonetheless, unlike RDC measurements
for folded proteins, RDC values for unfolded proteins can be difficult to interpret [204]. This is
due, in part, to the fact that prior to the measurement of RDC values, the protein of interest must
first be embedded in an alignment medium [60]. This induced steric alignment of unfolded
proteins may lead to results that do not fully capture the range of structures that an unfolded
protein can adopt in solution. Hence the absence of particular RDC values in polyacryalmide gel
(or any other alignment media) does not necessarily imply that a given conformation is not
present in solutions containing the unfolded protein of interest.
The formation of tau aggregates is likely a complex process as a number of factors have been
shown to influence the formation of tau aggregates in vitro [12, 177, 178]. Consequently, there
may be additional factors that contribute to the increased ability of the AK280 mutant to form
aggregates; e.g., a AK280 mutation leads to an overall decrease in the strength of the
intermolecular charge-charge repulsion between tau monomers that self-associate [155].
Nonetheless, our data demonstrate that small changes in the sequence of tau can lead to localized
structural changes in the unfolded ensemble that may affect tau's ability to form cross 3-
structure. Overall, our data suggest that small sequence-specific changes can promote tau
aggregation and that interventions that prevent the propagation of n-structure downstream from
aggregation-initiating sequences, may form the basis for therapies that prevent tau aggregation.
Methods
Energy-minima Mapping and Weighting
The EMW method constructs ensembles for unfolded proteins that are consistent with a
given set of experimental data. Our model for an unfolded ensemble consists of structures
corresponding to local energy minima and associated probabilities (weights) that are assigned to
the different conformations. For this work, the experimental measurement used to optimize and
validate the model ensembles are chemical shifts for the second tau microtubule binding repeat
[124]. In principle, EMW can be used with any given set of experimental data. In this
application we focus on chemical shifts that were available for both the K18 and K18AK280
constructs
The EMW method can be decomposed into three steps i) conformational sampling, ii) model
optimization, and iii) ensemble validation. Conformational sampling uses high temperature
molecular dynamics (MD) followed by minimization of the resulting structures (i.e. quenched
dynamics) to create a library of widely varying conformations representing minima on the
potential energy surface. Model optimization is performed to select a subset of these structures
and optimize weights that represent the relative prevalence of each structure. Validation is
performed by computing additional chemical shifts that not used to construct the ensemble and
comparing these data to experimentally measured carbonyl carbon shifts. In what follows we
outline each step of the EMW method.
Conformational Sampling
We used quenched molecular dynamics (QMD) to sample different local energy minima of
the R2 peptide. Conformational sampling was performed on a blocked peptide with the
sequence corresponding to the second microtubule binding repeat. A polar-hydrogen model of
the WT (VQIINKKLDLSNVQSKCGSKDNIKHVPGGGS) and AK280
(VQIINKLDLSNVQSKCGSKDNIKHVPGGGS) MTBR2 peptides were constructed using
CHARMM [157]. The N and C-termini were blocked using ACE and CBX residues defined in
the Effective-Energy Function-i (EEF1) model [140]. This sampling procedure consisted of
high temperature molecular dynamics (used to randomize the initial conformation of the protein)
followed by quenched dynamics. To ensure that a wide range of conformations was sampled,
constraints were imposed on the peptide for the high temperature and quenching steps.
Specifically, conformational sampling was performed in a series of molecular dynamics
simulations. In each simulation the end-to-end distance of MTBR2 was restrained to a pre-
defined value; i.e., 3A, 4A, 5A , ..., 70A, where the end-to-end distance was defined as the
distance between the Ca carbons on residue VAL1 and SER31 of the peptide. End-to-end
restraints were used to ensure that both compact and extended states were sampled during the
high temperature simulations. For each end-to-end distance, 4ns of high temperature MD at
1000K was performed with the EEF1 implicit model of solvent [140]. All simulations
employed a Berendsen thermostat to maintain the system temperature at the desired value [159].
Hydrogen bond lengths were held near their equilibrium values using SHAKE [160] and a 2 fs
timestep was used. Coordinates were saved every 10ps, yielding a total of 400 structures per end-
to-end distance. This procedure was applied to both WT and AK280 sequences, producing a total
of 27,200 structures for each sequence.
Each structure was then used to initiate a new MD trajectory which cools the system to 298K
over 40ps of simulation by coupling the sampled system (including atom coordinates and
corresponding velocities) to a Berendsen heat bath at 298K. At the end of this cooling
simulation, structures were minimized for 10000 steps using the Adopted Basis Newton Rhapson
algorithm [157]. Restraints were removed for the minimization step to ensure that minima on the
unbiased energy surface are sampled. Searching for minima in the vicinity of the randomized
conformation by cooling and equilibration followed by minimization rather than simply
performing direct minimization allows the structures to escape shallow local energy minima and
find more stable states.
As the conformation of PHF6* is of particular importance, additional simulations were
performed to ensure that a large range of PHF6* conformations were represented in the
ensembles. Each additional simulation constrained the PHF6* radius of gyration to adopt a pre-
defined radius of gyration (4A -5.9A) while the restricting the end-to-end distance of MTBR2 to
be near 9A. This was done because our initial data suggested that compact conformations of
MTBR2 were relatively undersampled after early QMD simulations. In total 31,200 local energy
minima were generated for the native polypeptide and 31,200 structures were generated for the
mutant structure. We refer to this set as our structure library.
We note that no single structure in our structure library had calculated backbone chemical
shifts that agreed with the corresponding experimental values. For example, amongst the 31,200
structures, we found one conformer that had a 13Ca chemical shift error of approximately lppm
(compared to the ensemble shift errors of 0.1ppm). In addition, this structure had a 13CO
chemical shift error of 2.3ppm (compared to the ensemble CO errors which were all below
0.9ppm).
Ensemble Optimization
The optimization procedure strives to obtain ensembles that have calculated chemical shifts
that agree with experiment. The function to be minimized is:
f({ o,, X , = (S (j)SP j)- S (j)) 2  (4.1)
where N is the number of structures in the ensemble, X is the Cartesian coordinates of the ith
structure, cow is the weight of the ith structure, r is the number of residues in MTBR2, S P (j) is
the experimentally determined Ca chemical shift of residue j, and S, (j) is the calculated Ca
chemical shift of residuej. Using the definition of S, (j) shown in Figure 15 we have:
f({oN,X,}N i=c s(j))-SEXp(j) S (4.2)
j=1 i
where S' (j) is the calculated chemical shift of residuej in structure X. Sj (j) is computed
using SHIFTX [2]. We note that reported errors for the experimentally determined chemical
backbone shifts are all approximately 0.1ppm [124]. Therefore, the experimental errors of
individual shifts are not explicitly included in equation (4.2). Lastly, errors reported in the text
represent - and are therefore in units of parts-per-million (ppm); i.e., the same units used for
chemical shift data.
We used a simulated annealing algorithm to minimize f in equation (4.2). To implement a
simulated annealing protocol we first need an initial ensemble. The candidate ensemble was
constructed by dividing the structure library into n different sets based on the radius of gyration
of the different conformers, (n was allowed to vary between 1 and >100, see below). One
structure was randomly chosen from each set to form the initial ensemble. This ensures that our
simulated annealing protocol begins with a set of structures that span many different radii of
gyration for the molecule. The weights for structures in this ensemble were calculated from the
relative energy of each conformation as follows:
(Ei-TS,)
e kT
co, = (4.3)
(Ej -TSJ
e kT
where the energy associated with each conformation, E, is the EEF1 potential energy, S is
the vibrational entropy, and T=298K [48]. This initial model (structures and weights) was the
starting point of our simulated annealing protocol.
In our simulated annealing protocol, one performs a number of Monte Carlo steps at a given
value of a control parameter (also referred to as the temperature). As the control parameter is
gradually decreased, the system approaches its global minimum [205]. Central to any simulated
annealing method is the protocol for decreasing the control parameter; i.e., the cooling schedule.
We use a cooling scheduled based on the work of Nulton et al. and described in reference [206,
207].
Each Monte Carlo step consisted of several stages:
* Generating a new candidate ensemble:
At each MC step, a structure from the current ensemble was replaced by a new structure
from the library of minima (structure library) sampled by QMD to create a new candidate
ensemble.
* Choosing weights for a given set of structures:
Given a new choice of 15 structures, weights were optimized using an minimization
algorithm that employs an interior-reflective Newton method, to find a set of weights, co,
which minimize [208, 209] equation 2.
Metropolis Acceptance Criteria
The new ensemble (structures and weights) is accepted or rejected based on a Metropolis
criterion.
The simulated annealing algorithm was implemented MATLAB (© Mathworks). The
number of Monte Carlo steps for a given value of the control parameter is as described in a
previous work [206].
To determine the appropriate number of conformers in each ensemble, we performed the
optimization procedure described above assuming that the ensemble had n structures, where n
ranged from 1 to >100. These calculations found that a minimum of approximately 15
conformers were needed to fit the Ca chemical shifts to within 0.1ppm, which is approximately
equal to the experimental error associated with these chemical shift measurements [124] and
well-below the error associated with SHIFTX chemical shift predictions [2]. Including
additional structures did not significantly improve the error.
Ensemble Validation
Validation consists of computing chemical shifts, using the final optimized model from, and
comparing these data to experimentally measured values that were not sued in step (ii). As
described in the text, 13Ca-chemical shifts were used to construct the model and 13CO and 1HN
shifts were used for validation purposes. The error between calculated and measured shifts is
computed using equation (4.2), with 13CO atoms substituted for 13Ca atoms. Models were
ranked by their error and the 30 models with the best agreement with the 13CO shifts were
selected for more detailed analysis as described in the text. To further test whether these models
could be used to calculated quantities not used in model construction we computed 'HN
chemical shifts from these thirty ensembles and compared these data to the corresponding
experimental values.
Identifying Locally Preserved Conformations
We searched for conformations of 6-residue subsequences that are present in every ensemble.
Six residues was a natural characteristic size for a local region of interest, as it is the length of
PHF6*. To this end, all structures in each ensemble of either WT or AK280 MTBR2 were
clustered using a matrix consisting of the pairwise rmsd backbone deviation of the each
contiguous six-residue segment. Structures were clustered using MATLAB (C Mathworks)
such that the maximum RMSD between two structures in a cluster was 2.5A. A range of
maximum RMSD values (1-6 A) were examined empirically, and it was found that a cutoff of
2.5A was sufficient to prevent similar conformations from being divided into separate clusters,
while also ensuring that clusters included a relatively homogeneous set of conformations. The
probability that a given cluster occurs in an ensemble is equal to the sum of the weights of all
structures that contain that motif. Preserved local structural motifs were found by identifying
clusters where the total weight of its structures was non-zero across all ensembles.
Structures for each cluster were visualized in VMD. To facilitate visualization of the overall
conformation associated with a cluster, an average structure for each cluster was generated after
5000 steps of steepest descent minimization to remove bad contacts (only the 6 residues were
minimized). Visual inspection verified that the energy minimized structures did not differ
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significantly from their un-minimized counterparts. All molecular structures were made with
VMD [163].
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Chapter 5: Models of K18
Introduction
Recently, residual dipolar couplings and radius of gyration measurements for the
microtubule-binding repeat domain of tau have been published [18, 19]. The microtubule-
binding repeat domain consists of the 130 residue region of tau encompassing the four
microtubule-binding repeats, MBR1 through MBR4, in Figure 18. The construct for the
polypeptide corresponding to the microtubule-binding repeat sequence has been designated K18
[19].
We first attempt an alternate modeling approach - to construct a model of the unfolded state
of K18 without utilizing experimental data, based on physical principles. However, we found
that this model was unable to fully reproduce experimental measurements. In particular,
agreement with residual dipolar coupling measurements could not be obtained. Thus, in order to
incorporate these K18 measurements into our analysis, we applied the previously described
EMW method to obtain and analyze ensembles incorporating the new data.
The Segment Model
In principle, one could efficiently sample unfolded state conformations from first principles
given a complete understanding of the physical interactions involved. At the present, the
intramolecular and solvent interactions which determine conformational preferences in the
unfolded state are not well characterized. Most potential functions are tested and validated on
folded states of proteins [138-140]. Ideally, these potentials should generalize to either folded or
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unfolded states of proteins. In practice, simplifying approximations, such as the absence of atom
polarizability, may limit the physical contexts to which these potentials can be generalized. Thus,
in the EMW method, we combined conformational sampling using a physical potential surface
with an empirical selection and weighting of conformations to construct conformational
ensembles [49]. With this approach, there exists a degeneracy of solutions - more than one set of
structures can be consistent with the available experimental data. Since different solutions can
exhibit different conformational properties, the conclusions one can draw from such models are
limited. In this chapter, we attempt to efficiently sample conformations of K18 without fitting to
experiment by proposing a hypothesis regarding the physical properties of the unfolded state.
Given the scarcity of stable long-range contacts in intrinsically disordered proteins, we
hypothesized that the distribution of conformational preferences could be described by a model
which accounts for local interactions but approximates sequentially-distant conformations as
independent. If this hypothesis is correct, one can sample conformations of the unfolded state by
utilizing distributions of local conformations from simulations of isolated sequence segments
(Figure 23A (1)). These isolated segments should include overlapping residues. For example, in
our implementation, we chose 8 residue segments with 3 residues of overlap (see methods) - the
first segment corresponds to residues 1-8 in the sequence, the second segment corresponds to 5-
12, the third segment corresponds to 9-16, etc. Once local segment conformational distributions
are generated, structures of the larger protein can be efficiently generated by successively
sampling conformations from these distributions. Each segment is aligned to the adjacent
segments using the overlapping residues (Figure 23A (2)). Duplicate atoms are removed and the
coordinates for the segments are merged into a single polypeptide chain which is minimized to
remove bad contacts (Figure 23A(3)). Figure 23B shows this process of chain elongation in three
dimensions using atomic coordinates sampled from local conformational distributions. We refer
to this method as the segment model. Further implementation details of this method are
discussed in the methods.
A
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Figure 23 Sampling an unfolded protein conformation from peptide segments. (A) Schematic of the method
for building structures for a polypeptide from segments. 1. Replica exchange simulations on peptide
subsequences are performed to construct distributions of segment conformations for overlapping
subsequences of the protein. 2. For each segment distribution from step 1, a single conformation is randomly
sampled and overlapping residues are aligned. 3. Duplicate atoms are removed and atoms from segments are
joined into a single polypeptide chain representing one realization of the protein conformation in the
unfolded state. The final structure is minimized to remove bad contacts. This process is repeated to sample
different conformations of the protein (B) The process of chain elongation shown in 3D, using atom
coordinates from peptide simulations. From left-to-right, top-to-bottom, each structure shows the alignment
and addition of a single local segment conformation to the overall chain. The bold line in the final structure
represents the combined chain representing the larger unfolded protein.
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The implication of this hypothesis is that if one can fully specify the conformational
distributions of local segments in the intrinsically disordered protein, then the conformational
distribution of the larger protein is fully specified. Thus a full characterization of the
conformational space does not require description of a conformational distribution of size O(sN)
(N is the number of residues in the protein of interest, s is the number of states available to each
residue), but rather O((N/n)sn) conformations describing the set of local conformational
distributions (n is the number of residues in the subsequence). In general n<N and therefore
(N/n)sn << sN. If such a model is adequate, the complexity associated with describing the
unfolded ensemble becomes far more tractable.
Statistical coil models (see page 21) can be thought of as a special case of the segment model
in which n=2 (Figure 24). Likewise an all-atom, full protein simulation can be thought of as a
special case of the segment model in which n=N. If one considers a spectrum of models for
intrinsically disordered proteins, the segment model corresponds to an intermediate degree of
detail (for 2<n<N) between statistical coil models and full protein simulations.
Statistical Coil Segment Model Full Protein Simulation
Figure 24 The segment model represents an intermediate level of detail for modeling intrachain interactions.
Statistical coil models generally model nearest neighbor effects (and volume exclusion), while all-atom MD
models include interactions between all atoms.
The segment model differs from the statistical coil model in that it can account for
interactions (other than volume exclusion) and correlated conformations within a segment.
Furthermore, in our implementation, local conformational preferences are derived from a
physical potential function modeling physiological conditions, rather than phi/psi propensities
tuned to reproduce RDC measurements under denaturing conditions [67, 68].
Results
The Segment Model
Models of K18 were constructed by sampling and connecting peptide conformations as
described in the methods section. 5000 structures were sampled (a comparable number of
structures are used in other stochastic models of the unfolded state [67, 68]). We began
evaluating the ensemble by comparing the ensemble-average radius of gyration to measured
values obtained by SAXS [18]. The segment model substantially underestimates the average
radius of gyration of the ensemble, computing a radius of gyration of 1.81nm, whereas the
measured RGYR of K18 is 3.8±0.3nm.
One explanation for this discrepancy is that intramolecular electrostatic interactions in the
implicit solvent potential are overemphasized, biasing the distribution of peptide conformers in
favor of compact structures [136]. Fully compensating for these effects requires an implicit
solvent potential that is better parameterized for unfolded states of proteins, which is beyond the
scope of this work. Another contributing factor to this discrepancy is that volume exclusion due
to the remainder of the protein is not accounted for in generating local conformational
distributions.
We examined whether experimental quantities could be reproduced by utilizing the existing
conformational distributions and sampling structures with a modified probabilitydistribution
which favors selection of extended conformations during the construction of K18 structures:
-2(Rg j -Rg E )2
P(s,j) = (5.1)
e_-(Rgi,k -Rg E 
)2
k
where P(s,j) is the probability of sampling peptide structure j at segment i when constructing a
K18 structure, Rgj is the backbone radius of gyration of peptide structure j at segment i, k
iterates through all structures at segment i, RgE is the backbone radius of gyration of a fully-
extended eight-residue peptide (8.5A), and A is the scaling parameter for favoring extended
conformers. This formalism is equivalent to introducing a harmonic potential that is centered at
the fully extended state with k as a force constant. For A = 0 this distribution reproduces the
uniform sampling of conformers from the REMD simulation. By biasing the local
conformational distributions towards more extended conformations, the distribution of the
generated K18 structures becomes more extended as well (Figure 25). One limitation of this
method is that the sampling of segment conformations is restricted to the existing sampled
conformations. Furthermore, since the free parameter, A , is fit to experiment, experimental
measures other than radius of gyration (i.e. chemical shifts and RDCs) must be utilized to
validate the correctness of the resulting ensemble.
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Figure 25 The effect of biasing sampling of segments towards more extended conformations. (A) The
distribution of K18 RGYR as X is varied from 0 to 1. (B) Example K18 conformations as X is varied from 0 to
1.
A parameter value ofA = 0.875 resulted in an ensemble with an average radius of gyration
equal to the experimental measurement of 3.8nm. We proceeded to compare this ensemble with
chemical shift and RDC measurements. For each of the structures in the ensemble, chemical
shifts were computed with SHIFTX and RDC values were computed with PALES and the
ensemble average calculated [2, 82]. Consistent with previous studies, ensemble averaged RDCs
were scaled by a constant scaling factor for comparison with experiment, as has been utilized in
previous models to equalize the range of simulated and experimental RDCs [67, 68].
Comparisons between the ensemble average H, Ca, and CO chemical shifts and experimental
measurements yielded reasonable agreement with root mean squared errors of 0.73ppm,
0.23ppm, and 0.77ppm, respectively - all within the prediction error of SHIFTX [78]. Agreement
with nitrogen chemical shifts was poor, with an error of 3.96ppm, however the prediction error
for nitrogen chemical shifts is substantially larger than for other atom types and the relationship
between nitrogen chemical shifts and protein structure is less-well understood [2]. The
incorporation of sidechain coordinates from the segment conformations into the K18 structures is
required for agreement with experiment. If sidechains are built and minimized from scratch after
construction of the K18 backbone instead of incorporated from the peptide coordinates, chemical
shift agreement is worsened, particularly for CO chemical shifts whose errors increase by 62%.
However ensemble average RDCs of the segment model do not exhibit agreement with
experiment (not shown). Possible reasons for this are examined in the discussion section. We
concluded that the current implementation of the segment model was insufficient to reproduce
the experimental properties of K18.
Energy Minima Mapping and Weighting Models of K18
We examined whether EMW could be used to select and weight structures to generate
models of K18 consistent with experiment [17, 49]. Since RDCs proved to be the key difficulty
in reproducing experimental measurements for the segment model, they were utilized in the
EMW optimization rather than chemical shifts. The previously described EMW protocol [49]
was adapted for RDCs (see methods for details) and 70 ensembles were generated.
Resulting ensembles were observed to be consistent with experimental Ca, CO, and H
chemical shifts to within prediction error. RDCs of these models were substantially improved by
the fitting. In contrast to the segment model, this procedure was able to show qualitative
agreement with measurements (Figure 26), though future work may utilize larger ensembles to
further improve the agreement with measured RDC values. For comparison, we generated EMW
models of AK280 forms of Ki 8 using available experimental data.
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Figure 26 Comparison between model RDCs (blue) and experiemt (green) of 10 EMW ensembles.
These ensembles were also examined for local conformational preferences at the K280
mutation site. This analysis differs from the previous study [49] in that it now incorporates the
additional experimental data into the model and examines these conformational preferences
within the context of K 8. A single local conformational preference was identified for both WT
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(Figure 27A) and AK280 (Figure 27B) forms of tau. Whereas there is a single local conformation
preference in WT Ki 8 corresponding to a bend centered at the mutation site, the corresponding
region in the AK280 form exhibits a local conformational preference for a kinked, but more
extended conformation. This is consistent with our previous hypothesis that a local
conformational preference for more extended-like conformations in disease-associated states of
tau may explain the differences in aggregation propensity and toxicity between the disease-
associated mutant and WT forms of tau.
A B
1278
N279
K280 78
SK281 N285 279
S284 L283 D283 L282 S284 3 D283 K281L283 D283 L282
Figure 27 Local conformational preferences of segments at the K280 mutation site for (A) WT K18 and (B)
AK280 K18.
Discussion
There are several possibilities as to why the segment model is unable to produce agreement
with experiment. The underlying hypothesis of the model may be incorrect - there may exist
subtle long-range correlations in the polypeptide chain that influence the distribution of
conformations populated by the protein. If this is the case, local conformations cannot be
sampled independently and the distribution of local conformational preferences may be altered
by such long-range interactions. Another issue is that the current implementation uses a generic
physical potential to obtain local conformational distributions, while in statistical coil models
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(which have exhibited some success in qualitatively reproducing RDCs), the residue-dependent
distributions are tuned to match RDCs from experiment. A better understanding of the physics of
the unfolded state and potential functions specifically designed to model intrinsically disordered
proteins may produce better agreement in the future. The implementation of the segment model
may also require further refinement - further studies investigating the effect of segment size may
be required. One may consider equilibrating the K18 structures using molecular dynamics to
further relax the chain conformation after joining the segments. Finally, as discussed in the next
chapter, there are limits to the accuracy of the current mapping methods between model
structures and experiment which need to be addressed. These issues represent potential future
avenues for these studies.
Further studies using EMW models of Kl8 should utilize additional structures to better fit the
RDC data. As Figure 26 shows, disparities remain between experimental and model RDC
signals. Furthermore, at the present, RDC measurements are only available for the wild-type
form of K18. The availability of RDC measurements for disease-associated mutant forms of K18
in the future will improve the quality of comparison between wild-type and disease associated
forms of K18. Nevertheless, these findings represent a first step in modeling the entire tau
microtubule-binding repeat domain, and provide additional support for our previous hypothesis
that the AK280 mutation affects the local conformational preference near the PHF6*
aggregation-initiation site by favoring extended local conformations.
102
Methods
Sampling Conformations of K18 with the Segment Model
Replica Exchange Molecular Dynamics of Segment Peptides
The setup of the molecular dynamics simulations used to generate segment conformation
distributions is comparable (and partially inspired by) to simulations by Ho and Dill in which
replica exchange simulations were performed on peptide fragments of folded proteins [210].
A local sequence size of 8 residues was chosen for the size of the peptides used in the
segment simulations, approximately the average persistence length of a polypeptide [67]. The
sequence of K18 was divided into 26 peptides of 8 residues each, with an overlap of 3 residues
between adjacent segments. By varying the length of the peptide, one effectively changes the
length-scale of local interactions being accounted for, moving along the spectrum of model detail
represented in Figure 24. Using a local sequence size of 2 residues, one obtains a statistical coil
model where the phi/psi propensities are defined by the energy function. Using a local sequence
size that is equal to the length of the protein, the simulation is effectively a replica exchange
simulation of the entire protein. The ultimate choice of the segment size is a parameter of the
model, and our choice was made to strike a balance between these two extremes. Furthermore, a
similar replica exchange protocol has been used to sample conformations of 8 residue peptides in
a previous study [210].
Each segment was simulated using 10ns of replica exchange molecular dynamics [73]. The
first 5ns of REMD simulation was discarded as equilibration and only the last 5ns of simulation
was used for the conformational distribution. Previous studies showed that backbone entropy of
peptides of this size typically equilibrates within 3.5ns or less [210]. REMD simulations were
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run in heat baths exponentially spaced between 260K and 700K. Exchanges were performed
every ips. Inspection of the REMD trajectories confirmed that exchanges frequently occurred
between all temperatures. Structures from the room temperature (298K) heat bath are saved prior
to each exchange, generating 5000 structures for each segment. 26 segments are required to
cover the entire sequence of K18, and thus 130,000 segment conformations are generated in
total.
Constructing K18 Structures from Peptide Fragments
The simplifying approximation of the segment model is that conformations of sequentially-
distal regions of the protein are independent. Thus, structures of K18 are constructed by
independently sampling and joining peptide conformations of segments of the K18 sequence.
This scheme is comparable to the structure-generation method in statistical coil models [68].
However, instead of building protein structures one residue at a time, the sequence is extended
by independently sampling and adding one peptide-segment at a time. Starting with the N-
terminal segment, each subsequent segment is independently sampled from its REMD trajectory
and aligned using the backbone atoms of the 3 overlapping residues. For each K18 structure
sampled using this method, a PDB file is created with duplicate atoms erased and residues
renumbered.
Each K18 structure was minimized to remove bad contacts using 1000 steps of steepest
descent minimization followed by 1000 steps of adopted basis newton-raphson minimization.
Inspection of the resulting structures showed that this minimization protocol removes bad
contacts while preserving the overall topology.
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Computing Experimental Quantities
Backbone radius of gyration, chemical shifts, and residual dipolar couplings were computed
for each K18 structure. Ensemble averages were compared with experimental measurements of
chemical shifts [123, 124], residual dipolar couplings [19], and the radius of gyration [ 18].
Backbone radius of gyration was computed in CHARMM [157]. Residual dipolar couplings
were computed by using REDUCE [211] to add non-polar hydrogens and PALES [82] to
compute RDCs from the resulting all-atom structures. Chemical shifts were computed using
SHIFTX (SHIFTX includes a built-in procedure to add missing non-polar hydrogen atoms) [2].
Computing ensemble averages across structures is performed as previously described [49]. In
the segment model, each sampled K18 conformation is given equal weight. For ensemble
averages of RDCs, a single scaling parameter is used to rescale the range of the RDC signal, as
has been done in previous studies [67, 68].
Generation and Analysis of EMW Ensembles for K18
EMW was used to generate 70 ensembles of K18 consistent with experiment as previously
described [49]. For WT K18, ensembles are fit against the experimentally measured RDC signal
[19]. The resulting ensembles were consistent with measured Ca, CO, and H chemical shifts to
within prediction error. Only the 30 ensembles closest to the experimentally measured RGYR
were used for further analysis. Since RDC measurements are not available for AK280, chemical
shift measurements were used for the optimization of ensembles. As with the WT ensembles, the
30 AK280 ensembles closest to the experimentally measured RGYR for K18 are used for further
analysis.
Since K18 structures are generated from the local distributions, the identification of local
conformational preferences was performed by clustering the peptide conformations using
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MMTSB [212] with a 2.5A cluster cutoff and identifying local conformational segment clusters
present in K18 structures across all ensembles.
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Chapter 6: Future Work
This work, in conjunction with recent experimental studies, represents a series of early
approaches to characterizing structural details of tau [18, 19, 122-124]. The construction of more
detailed models of tau protein will be facilitated by improvements to general methods for the
characterization of IDPs.
The mapping between model structures and experimental measurements is a key step in the
modeling of intrinsically disordered proteins such as tau. To determine ensemble averages from
calculated ensembles one needs to first calculate properties from individual structures.
Significant uncertainty associated with mapping individual structures to experimental properties
is clearly undesirable as this leads to uncertainty in knowing how well the ensemble agrees with
the experimentally determined result, which corresponds to an ensemble average. For example,
most commonly used structural chemical shift prediction methods have an associated error on
the order of lppm, but the error can vary widely depending on the atom type [2]. Measured
chemical shifts of intrinsically disordered proteins often deviate from their random coil values by
less than 1ppm and these deviations are often interpreted as indicative of residual conformational
preferences [123]. Thus, at present the mapping between model structures and experimental
values introduces a large degree of uncertainty with regards to model optimization, interpretation
and validation.
Another difficulty in modeling an unfolded ensemble is the degeneracy of the solution space.
Given a limited amount of structural information there exist multiple structural ensembles
consistent with the available experimental data. Since inclusion of additional independent
measurements decreases the size of the solution space, one approach to this problem is to obtain
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a large number of independent measurements (although the effect of different chemical
environments on the structural ensemble can complicate data interpretation). However, what is
even more problematic is that given the large size of the solution space, it is likely that
degeneracy will be a problem for IDPs even when a relatively large set of experimental data are
used.
Physics-based models can play a role in addressing the problem of solution degeneracy. By
including constraints imposed by knowledge of the underlying physics of the system, one can
both reduce the space of solutions as well as quantitatively examine whether those physical
assumptions are consistent with the experimental data, thus gaining deeper insight into the
properties of the ensemble. The segment model is an attempt to account for physical interactions
determining local conformational preferences while still allowing for efficient generation of
conformers. While additional work is necessary to enable such models to predict experimental
quantities, I believe that such approaches will enable greater insights into the unfolded state of
intrinsically disordered proteins and potential mechanisms of aggregation.
Finally, the most important extension of this work is to utilize these structural insights in the
design of therapeutics which target tau. We have proposed potential approaches for doing so in
chapter 2. Other recent reviews have also discussed strategies for therapeutic targeting of
intrinsically disordered proteins [129]. Perhaps the most critical endpoint for these structural
characterizations is to establish a basis for the rational design of therapeutics for
neurodegenerative diseases.
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Appendix: Residual structure within
the disordered C-terminal segment
of p21Wafl/Cipl/Sdil and its
implications for molecular
recognition
(Note: Experimental Sections of this Appendix were performed and written by collaborators Mi-Kyung
Yoon, Byong-Seok Choi, and James J. Chou. Other sections of this were written collaboratively with Veena
Venkatachalam, an undergraduate student. This work was published as M.-K. Yoon, V. Venkatachalam,
A. Huang, B.-S. Choi, C. Stultz, and J. Chou, "Residual structure within the disordered C-terminal segment
of p21 Wafl/Cipl/Sdil and its implications for molecular recognition," Protein Science., vol. 18, pp. 337-
347, 2009.)
Abstract
Probably the most unusual class of proteins in nature is the intrinsically unstructured proteins
(IUPs), because they are not structured yet play essential roles in protein-protein signaling. Many
IUPs can bind different proteins, and in many cases, adopt different bound conformations. The
p21 protein is a small IUP (164 residues) that is ubiquitous in cellular signaling, e.g., cell cycle
control, apoptosis, transcription, differentiation, and so forth; it binds to approximately 25
targets. How does this small, unstructured protein recognize each of these targets with high
affinity? Here, we characterize residual structural elements of the C-terminal segment of p21
encompassing residues 145 - 164 using a combination of NMR measurements and molecular
dynamics simulations. The N-terminal half of the peptide has a significant helical propensity
which is recognized by calmodulin while the C-terminal half of the peptide prefers extended
conformations that facilitate binding to the proliferating cell nuclear antigen (PCNA). Our results
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suggest that the final bound conformations of p21(145-164) pre-exist in the free peptide even
without its binding partners. While the conformational flexibility of the p21 peptide is essential
for adapting to diverse binding environments, the intrinsic structural preferences of the free
peptide enables promiscuous yet high affinity binding to a diverse array of molecular targets.
Introduction
Many proteins adopt a well-defined tertiary structure under physiological conditions, and this
structure largely determines protein function. However, there is a class of proteins known as
intrinsically unstructured proteins (IUP) that also plays specific roles in protein-protein
recognition. Some well-known examples include the phosphorylated kinase-inducible domain
(pKID) of the cAMP responsive element binding protein (CREB) [213], the transcriptional
activation domain (TAD) of p53 [214], and the GTPase-binding domain (GBD) of the Wiskott-
Aldrich syndrome protein (WASP)[215]. Spectroscopic studies suggest that these intrinsically
unstructured proteins are not completely random, but can exhibit residual secondary structural
preferences. For example, NMR studies demonstrated that the linker helix of p2 7 Ki pl has a
nascent secondary structure in its free state [216] although it is largely unstructured in solution
[217]. It is increasingly apparent that residual structure of intrinsically unstructured proteins
(IUPs) plays crucial roles in molecular recognition [22, 218, 219]. In this regard, it has been
suggested that the classic protein structure-function paradigm for IUPs be re-assessed and that
protein function for these systems can be understood using a formalism that models the IUP
structure as an ensemble of distinct conformations [22, 220, 221].
p21Wafl/Cipl/Sdil (hereafter referred to as p21) is an IUP involved in the regulation of the cell
cycle [222]. p21 was first identified as a cyclin-dependent kinase (Cdk) inhibitor [223] that
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mediates the GI/S arrest [224] and later was found to function in apoptosis [225], differentiation
[226], transcription [227], DNA synthesis control [228] and stem cell self-renewal [229]. The C-
terminal region of p21, which is unique among the Cip/Kip family of Cdk inhibitors, interacts
with a large array of proteins, including the proliferating cell nuclear antigen (PCNA) [230, 231],
calmodulin (CaM) [232], SET [233], c-Myc [234], and E7 oncoprotein of human papilloma virus
16 (HPV-16) [228].
How does p21, a small protein of 164 residues, physically recognize so many structurally
dissimilar proteins without sacrificing binding affinity? The binding diversity of the C-terminal
segment of p21 has been attributed to its ability to acquire different conformations upon binding
to distinct targets [235]. Although the far UV CD spectra suggest that residues 145-164
(p21(145-164)) is unstructured, this peptide adopts a well defined structure having a helical N-
terminal region and an extended strand C-terminal region when bound to PCNA [15]. Based on
previous examples of CaM-substrate binding [236] and CD measurement of mutant p21(145-
164) [235], p21(145-164) is likely to acquire a helical conformation when bound to CaM.
In this study, we combine NMR measurements of free p21(145-164) with molecular
dynamics (MD) simulations to obtain models for the unfolded ensemble of the free peptide at a
physiologically relevant temperature and pH. We found that the N-terminal half of the peptide
has a significant amount of residual helical structure and the C-terminal half has a preference for
extended conformations in the unbound state of p21(145-164). NMR dipolar coupling
measurements of the CaM - p21(145-164) complex indicate that the peptide is helical when
bound to CaM, which in turn suggest that the region of peptide with helical preference is likely
to interact with CaM. On the other hand, the C-terminal loop-like region of the peptide adopts an
extended conformation when bound to the PCNA [15]. Our results show that the structure
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adopted by p21(145-164) upon binding to CaM or PCNA already exist in the free peptide in
significant population and suggest that the pre-formed structural elements of p21(145-164)
contribute to its binding specificity.
Results
Residual secondary structure in p21(145-164) detected by NMR
spectroscopy.
The 1H- 15N HSQC spectrum of '5N-labeled p21(145-164) (Figure 28) showed poor
dispersion (< 1 ppm) of amide proton chemical shifts, consistent with a largely unstructured
peptide as observed by far-UV CD spectroscopy [235]. To investigate whether there is any
residual structure in p21(145-164), we measured 13C' and 1Ha chemical shifts, as well as the 3-
bond 3JHN-He coupling constants. The 13Ca and 'H' chemical shift values are very sensitive to
local conformation and thus their deviations from the values of random coil, known as secondary
chemical shifts, are indicative of secondary structure [237]. Secondary shift analysis is the most
widely-used method for detecting residual structural elements in largely unstructured polypeptide
chains [238-240]. The 13Ca secondary chemical shift of p21(145-164) (Figure 29A) shows that
the N-terminal half of the peptide, encompassing residues Met147 - Lys154 is partially helical
on average, while its C-terminal half shows a preference for extended conformations. In
agreement with the 13C' shifts, the 'H' secondary shifts (Figure 29B) are consistent with an
increased propensity for helical conformation for the N-terminal segment Thr148 - Arg155.
However, the 1H' shifts for the C-terminal half of the peptide are not characteristic enough to
draw any conclusions on the secondary structure preferences. Independent from the chemical
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shifts, the deviations of the 3JHN-Ha coupling constants from random coil values (Figure 29C) also
suggest helical tendency of the N-terminal half of the peptide, Thr145 - Lys 154.
The experimental chemical shifts and scalar coupling constants together indicate that the N-
terminal half of the peptide is helical, on average, under physiological conditions. While the
13C~ chemical shifts of residues Leu157 - Lys163 suggests that this region is extended on
average (Figure 29A), the lH' secondary shifts (Figure 29B) and the 3JHN-H, deviations (Figure
29C) are less conclusive.
Modeling the unfolded state ofp21(145-164) with MD simulations.
NMR measurements for unfolded proteins correspond to ensemble averages over a number
of structurally dissimilar states and therefore do not provide information about the underlying
distribution of conformers in the ensemble. To further our understanding of the conformers that
make the unfolded ensemble, we used molecular dynamics (MD) simulations to generate
structural ensembles which agree with our experimental data.
Our method, energy-minima mapping and weighting (EMW), associates a statistical weight
with each structure that corresponds to the probability that the given protein samples that
conformation. The application of EMW presented here is similar to that previously described
[49] and relies on obtaining NMR chemical shift data for a free peptide in solution, and
optimizing structural ensembles containing energetically favorable conformations of that peptide
to minimize the error between the calculated chemical shifts and the experimentally measured
values. The resulting ensembles agree with the experimental values, while also fulfilling physical
constraints imposed by the potential energy function.
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As the construction of an unfolded ensemble is an underdetermined problem, there may be
several ensembles that agree with any given set of experimental constraints. Therefore EMW
does not strive to construct one ensemble that models the unfolded state of p21(145-164).
Instead, we generate multiple ensembles that are all consistent with a given set of experimental
data, and focus our analysis on local structural motifs that are present across ensembles.
EMW was used to construct 250 ensembles using absolute 13C, chemical shifts. The 250
ensembles were then ranked according to their ability to reproduce experimentally determined
amide nitrogen chemical shifts, which were not used in the optimization procedure. The ten
ensembles best able to reproduce amide nitrogen chemical shifts were chosen for further
analysis. Calculated 13C, chemical shifts for these ten ensembles were in excellent agreement
with experiment (Figure 29), and nitrogen chemical shifts were all within 1.5ppm of the
experimental values (an error comparable to that of available chemical shift prediction
algorithms [2]). 1Hct chemical shifts were also computed for these ten ensembles, which
resulted in errors within 0.2ppm, which is also comparable to the error associated with available
chemical shift prediction algorithms [2].
To identify local conformations preserved across ensembles, all structures were clustered
based on the rms backbone deviation of contiguous 6-residue subsequences in p21(145-164). A
characteristic length of six residues was chosen as the local region size for this analysis since a
crystal structure of a bound state of p21(145-164) contained local structured regions
approximately six residues in length [15]. Clustering all contiguous 6 residue segments resulted
in 225 distinct clusters. Each cluster is representative of a local conformation within p21(145-
164). The total weight associated with a given cluster in an ensemble is given by the sum of the
weights of all structures in the cluster. A given cluster is said to be preserved across all ten
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ensembles if it has a non-zero weight in each ensemble. Using this definition, only 5.8% of the
clusters were preserved across all ensembles.
A preserved structural motif that is present in all independent ensembles is likely required to
reproduce the experimental data. Consequently, we consider such locally preserved structures to
represent local conformational preferences. Structures of conserved local conformations offer a
more detailed view of ensemble characteristics than ensemble averaged experimental secondary
chemical shifts.
Conformational preferences for p21(145-164) are shown in Figure 31. Several points are
clear from Figure 31. First, every residue in p21(145-164) is found in a 6-residue segment that
has an extended conformation. Hence, the simulations predict that each residue can adopt an
extended state in solution, including the N-terminal residues that have positive secondary Ca
chemical shifts (Figure 29A). What distinguishes the N-terminus is the fact that these residues
can also adopt helical conformations (Figure 31). Three conserved N-terminal helical clusters
were found, corresponding to preformed helical states in the unfolded ensemble, in the six-
residue regions corresponding to residues 147-152, 148-153, and 149-154. Residues 153-158
can also adopt a loop/turn conformation in solution. Lastly, the simulations predict that residues
159-163 have a distinct preference for only extended states.
It was previously reported that residues (146-151) in PCNA-bound form of p21(139-160)
forms a 310 helix, while the C-terminal region spanning residues 152-160 adopts an extended
strand which hydrogen bonds to a neighboring P strand in PCNA (Figure 32A, B) [15]. We
sought to determine whether comparable local conformational preferences are predicted for the
unfolded ensemble representing the unbound state. We find that the 6 residue subsequence
ranging from residues 147 to 152 can adopt a helical conformation in solution and that the
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subsequence consisting of residues 155-160 adopts an extended state, suggesting that there local
structural preferences in the unfolded ensemble similar to those adopted by the bound form of
p21(139-160) (Figure 32C).
Helical mode of p21(145-164) binding to Ca2+-calmodulin from NMR
dipolar couplings.
Based on CD measurements of mutant p21(145-164) [235] and the previous knowledge of
CaM-binding peptides [236], we expected p21(145-164) to be helical upon binding to CaM.
Previously, at least 180 CaM recruitment signaling (CRS) motifs were identified and classified
based on the spacing of the hydrophobic residues of CRS that make major hydrophobic
interaction with CaM [236]. However, p21 peptide contains no sequence that conforms to any of
these known CRS motifs.
In order to confirm the helical mode of p21(145-164) binding to Ca2+-CaM, two types of
residual dipolar couplings (RDCs), 'DNH and 1DCuH, were measured for Ca2+-CaM in complex
with p2 1 (145-164) in a liquid crystalline medium containing 18 mg/ml filamentous phage Pfl.
RDCs have been successfully used to determine the binding mode of CaM-interacting peptide to
Ca2+-CaM [241, 242]. The experimentally measured RDCs of CaM in complex with p21(145-
164) were fitted to the free Ca2+-CaM structure (Figure 33A) and CaM/peptide complexes using
the singular value decomposition (SVD) method [243]. The measured RDCs show very poor
agreement with the dumbbell-shape crystal structure of the free Ca2+-CaM (Figure 33A) because
the conformation of Ca2+-CaM bound to p21(145-164) is very different from that of free Ca 2 +-
CaM. Among the 13 CaM/peptide complexes tested, including the complexes that show different
types of binding mode, the best correlation was obtained for CaM/CaMKII complex that belongs
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to the 1-10 class [244] (Figure 33B). This suggests that p21(145-164) adopts a known CaM-
binding mode (possibly the 1-10 class) in which the CaM-interacting region is helical.
Discussion
The NMR data and molecular dynamics simulations are used to explain the binding
promiscuity and specificity of p21(145-164) mediated protein-protein signaling. The binding
promiscuity can be attributed to the structural plasticity, or unstructured nature, of the peptide,
which allows it to adapt to the distinct structural environments of many different target proteins.
A fundamental question remains - if the peptide is largely unstructured, how does it bind
multiple proteins with high affinity?
We first examined the residual structure of p21(145-164) in solution and compared locally
preferred conformations to regions of structure in bound forms of p21(145-164). The crystal
structure of p21(139-160) bound to PCNA shows that residues Ser146 - Tyrl51 of p21 forms a
310-helix which is involved in hydrophobic interaction with PCNA, whereas residues His152 -
Serl60 of p21 adopts an extended P-strand conformation which interacts with PCNA [15]. We
have shown the helical preference of the N-terminal region of the p21(145-154) which
corresponds to the helical region of the PCNA-bound structure . The chemical shifts and scalar
couplings for residues Arg155 - Lys163 show no sign of residual helical structure and the MD
simulations suggest that the helical and extended portions of p21 that bind PCNA exist in the
free state prior to binding (Figure 32). The recognition for PCNA in this case comes from the
fact that residues His152 - Serl60 of p21 have a preference for conformational arrangements
which readily expose the positively charged residues for specific interactions with PCNA. In the
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extended, uncoiled conformation of the p21 peptide, residues Arg155 and Arg156 readily
interact with the negatively charged Asp 122 and Asp29 of PCNA, respectively.
In addition, the NMR structure of Cdk4-bound p2 1 (141-160) also includes a helical region
(residues 149-156) [16]. Similarly, model ensembles of the unbound state generated by EMW
suggest that the region corresponding to residues 149-154 can adopt helical conformations (see
Figure 31).
We then examined the mechanism of recognition between p21 and Ca 2+-CaM. Although the
NMR resonances of the p21(145-164) peptide bound to CaM are extremely broad due to
chemical exchange, the resonances of CaM are much less affected by the peptide and thus allow
accurate structure measurement. An extensive set of RDCs measured for CaM bound to the
p21(145-164) peptide indicates a CaM-substrate interaction mode in which the substrate adopts
an a-helical conformation. For the free p21(145-164) peptide, the NMR chemical shifts and
scalar couplings together show that residues 147 - 154 have significant helical propensity, and
MD simulations suggest that the N-terminal region has a strong preference for helical
conformations while helical structure is absent in the C-terminal region. We believe the residual
helical segments observed in the free p2l(145-164) peptide is responsible for its initial
recognition with Ca2+-CaM. The helical structure is then stabilized by the binding. Overall, the
structural propensities of the free p2 1 (145-164) peptide correlate well with the different
structures adopted by p21 upon binding to different targets. This observation suggests that pre-
existing residual conformations of p21 provide the initial recognition for the target proteins.
Bindings then further stabilize these residual conformations. The p21 peptide provides an
interesting example of how residual structural elements of an IUP are involved in specific and
diverse protein-protein signaling.
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Materials and Methods
Cloning, Protein Expression and Purification
The peptide p21(145-164) was expressed as a C-terminal in-frame fusion to the trpLE protein
containing the N-terminal 9-His tag. A pair of Asp-Pro residues was engineered between trpLE
and p21(145-164) for acid catalyzed cleavage to release the p21 peptide from the fusion protein.
The expression vector was constructed by inserting the DNA fragment of p21(145-164) into the
C264 vector, a gift from Dr. M.E. Call, Harvard Medical School, Boston.
Escherichia coli strain BL21 (DE3) that express the trpLE-fused p2 1 (145-164) were cultured
in M9 minimal media for isotope labeling. The cell cultures were grown at 37 'C to OD 600 of 0.6-
0.8 before overnight induction at 25 'C with 0.4 mM IPTG. Inclusion bodies were dissolved with
a buffer containing 50 mM Tris, pH 8.0, 0.2 M NaC1, 6 M guanidine HC1, 10 mM imidazole.
The cleared solution was bound to Ni2+ affinity column (Sigma) and eluted in 50 mM Tris, pH
8.0, 0.2 M NaC1, 6 M guanidine HC1, 400 mM imidazole. The eluted fusion protein was dialyzed
against water to remove guanidine HC1. The precipitant was pelleted by centrifugation at 3000
rpm for 30 min. Incubation of the pellet in 0.1N HCI at 37 'C for 3 days released the p21(145-
164) peptide from the trpLE fusion partner. The released peptide was dialyzed against water,
lyophilized, and purified by reverse-phase HPLC on a C18 column (Grace-Vydac) with a
gradient of water containing 0.1% trifluoroacetic acid (TFA) to acetonitrile containing 0.1%
TFA. The resulting peptide was lyophilized and dissolved in 100 mM KC1, 10 mM CaCl2, pH
6.5.
CaM was expressed and purified as previously described [245]. Isotropic NMR samples were
prepared in 100 mM KC1, 10 mM CaCl2, pH 6.5 in 93 % H20/7% D20. The aligned sample
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contained 18mg/ml filamentous phage Pfl (Asla Labs, Riga, Latvia), 100 mM KCi, 10mM
CaC12, and ImM sodium azide, pH 6.5 in 93 % H20/7% D20.
NMR Spectroscopy
All NMR spectra were collected at 300 C on Bruker and Varian spectrometers operating at 1H
frequencies of 500 MHz or 600 MHz and equipped with cryogenic probes. The sequence-
specific backbone assignments were accomplished using pairs of HNCACB/CBCA(CO)NH and
HNCA/HNCACB on the 15N, 13C-labeled CaM in complex with unlabeled p21 (145-164) and
'
5N, 13C-labeled p21(145-164), respectively. Two types of backbone RDCs, 1DNH and 1DCaHa,
were measured on the '5N, 13C-labeled CaM in complex with unlabeled p21(145-164). The 'H-
15N RDCs were obtained from 1JNH/2 and ('JNH+lDNH)/2, which were measured at 600 MHz ( H
frequency) by interleaving a regular gradient enhanced HSQC and a gradient-selected TROSY,
both acquired with 80 ms of 15N evolution. The 1H-13Ca RDCs were measured at 600 MHz ('H
frequency) using the 3D CT-(H)CA(CO)NH without 1H-decoupling [246]. Measurement of 3JN_
Ha coupling constant for determining backbone 0 angle was carried out on the 15N, 13C-labeled
p21(145-164) using the 3D HNHA experiment [247]. The 'H chemical shifts were referenced
directly to external 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS) in D20 and 13C chemical
shifts are indirectly referenced to 0 ppm proton using the method in Wishart et al. [248].
Data processing and spectra analyses were done in NMRPipe [249], CARA [250], and
Sparky (http://www.cgl.ucsf.edu/home/sparky). RDCs were extracted by subtracting isotropic
couplings from the aligned couplings. Fitting of RDCs to structures was done by singular value
decomposition [243], using the program PALES [82]. The goodness of fit was assessed by both
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Pearson correlation coefficient (R) and the quality factor (Q) { }. The 1H-"3 C' RDCs were
normalized to the 'H-15 N RDCs by a scaling factor of 0.5.
Molecular dynamics simulation
Energy-minima Mapping and Weighting (EMW)
To construct an ensemble that represents the unfolded state of p21(145-164), we employ
EMW method [49]. Details of EMW are described in detail below.
(i) Conformational Sampling
The goal of conformational sampling was to generate a library of energy-minimized
structures with representatives from all regions of conformational space accessible to the peptide.
This was done using quenched molecular dynamics (QMD) (6). To ensure that both compact
and extended structures were adequately sampled, QMD was carried out at 50 different end-to-
end distance constraints, spanning a range from 4A to 53A. At each distance constraint, a polar
hydrogen model of an extended peptide having the sequence TSMTDFYHSKRRLIFSKRKP
(p2 1(145-164)) was constructed using CHARMM, and a harmonic penalty was introduced to
enforce the desired distance between 13Ca of T145 and 13Cx of P164. The structure was then
minimized using 500 steps of steepest descent minimization followed by 10000 steps of
minimization using the Adopted Basis Newton Rhapson algorithm. Next, the structure was
heated to 1000 K for 10 ps and allowed to equilibrate for 10 ps, before high temperature MD was
run for 3 ns. Throughout the simulation, a Berendsen heat bath was used to maintain the
temperature [159], and the EEF1 energy function (a Gaussian solvent exclusion model for the
solvation free energy) was used to assign energies [140]. The SHAKE algorithm was employed
to hold bonds to hydrogen atoms fixed near their equilibrium values, allowing for a 2 fs time step
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during high temperature MD simulations [160]. The peptide's coordinates were saved after
every 5000 steps (10 ps) of high temperature MD simulation, yielding 300 structures per end-to-
end distance constraint. Thus, 15000 structures were created using high-temperature molecular
dynamics.
With end-to-end distance constraints still in place, each of these structures was coupled to a
Berendsen heat bath at 298 K and cooled for 40 ps, at which point the end-to-end constraint was
removed and the system was minimized using 10000 steps of Adopted Basis Newton Rhapson
minimization [159]. Cooling and equilibrating each structure before minimization gave the
system a chance to escape shallow local energy minima, thereby making more stable structures
accessible. The 15000 structures obtained in this manner comprised our structure library.
(ii) Model Optimization
A goal of this procedure is to find ensembles that represent the solubilized p21 peptide,
where each ensemble consists of 15 structures and their associated weights. Accordingly, the
optimization stage of EMW involved generating such ensembles by choosing structures from the
conformational library generated in the first step and assigning weights to these structures.
Experimentally determined 13C' NMR chemical shifts for the peptide were used to determine
what constituted an optimal ensemble; structures and weights were assigned to minimize the root
mean square error between 13C, chemical shifts computed from the model using SHIFTX and
13Cc chemical shifts that were experimentally measured [2]. This was done by minimizing an
appropriate error function, f given by:
r N 2
, (1S)=(j)) t)S ( j) (A.1)j = 1
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where N is the number of structures in the ensemble (N = 15), X is the ith structure, cow is the
weight of the ith structure, r is the number of residues in the peptide for which experimental
chemical shift data is available (r = 18), Sx (j) is the calculated Ca chemical shift of residuej in
structure X, and S xP (j) is the experimentally determined 13C, chemical shift of residuej [49].
A simulated annealing protocol using a cooling schedule based upon that described by
Nulton et al. was implemented [207]. Each ensemble was generated from an initial ensemble
consisting of 15 Boltzmann-weighted structures chosen at random from the conformational
library [48]. This initial ensemble was subjected to an iterative simulated annealing protocol that
minimized the rmse between measured and predicted 13Ca chemical shifts. Each step of the
annealing protocol consisted of carrying out Monte Carlo steps at a given value of the control
parameter T, which is analogous to the temperature in physical systems, until the system had
equilibrated.
A Monte Carlo step consists of perturbing the ensemble by replacing one conformer in that
ensemble with a conformer from our structure library. Weights for all structures are then
reassigned to minimize the overall error, f The number of Monte Carlo steps for a given value
of the control parameter, as well as the schedule used to decrease the overall temperature, is as
described in a previous work [206]. Overall, 250 ensembles were generated using this simulated
annealing protocol.
(iii) Model Validation
The rmse between predicted nitrogen chemical shifts and measured nitrogen chemical shifts
for each ensemble was calculated for each of the 250 models generated, and those ensembles in
which this error was less than 1.5 ppm were taken to be valid models based upon their ability to
predict experimentally measured amide nitrogen chemical shifts. Ten valid ensembles were
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found that reproduced the NMR chemical shift data well, due to the underdetermined nature of
the problem, but we accounted for this by using all ten of these independently generated,
validated structural ensembles in our analysis and focusing on those structural motifs that were
preserved across all of them.
Procedure for Identifying conserved preformed structures
Two different methods were employed to find structural motifs that were present across all
validated model ensembles of the unfolded state. Since studies have shown that bound states of
p21(145-164) adopt helical conformations, we looked for evidence of preformed helical motifs in
the unfolded ensemble. We then sought to identify other structural motifs suggested by the
model ensembles.
Identification of conserved local structure by clustering
We sought to identify other types of local structural motifs in the peptide. To this end, all
conformers were clustered based on local conformational preferences. Since the helical region in
the crystal structure of PCNA-bound p21 is six residues in length, we defined the characteristic
size of a local structural motif to be six residues. To account for all local motifs, every six
residue subsequence of p21(145-164) was analyzed to find preserved conformations. This was
accomplished by clustering based upon backbone atom RMS deviations within each six-residue
window of interest. Clustering was carried out in MATLAB (C Mathworks) such that the
maximum rmsd between any two structures was 2.5 A. Clustering based on other window sizes
(5, 7, and 8 residues in length) was performed to ensure that analysis was relatively insensitive to
the choice of window size. Clusters that were represented in all ten ensembles were identified as
preserved local structural motifs.
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Figure 28 The 1H-15N heteronuclear single quantum correlation (HSQC) spectrum of the 'SN-labeled p21(145-
164) recorded at 1H frequency of 500 MHz, pH 6.5, and 30 oC. All of the backbone 'HN and sN are assigned
except for Arg156.
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Figure 29 NMR measurements of residual secondary structures of p2 1(14 5 -164 ). (A) Deviation of 13Ca
chemical shifts of p21(145-164) from the random coil values [251]. A 3Ca = 13Ca (p21) - 13C, (random coil).
(B) Same as in (A) for the 1H' chemical shifts. (C) Deviation of the 3 JHN-Ha coupling constants of p2 1 (145-
164) from random coil values [252]. A 3JHN-Ha 3JHN-Ha (p 2 l) - 3 JHN-Ha (random coil). Data are not available
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Figure 30 Comparison of experimental Ca chemical shifts and Ca chemical shifts calculated using the
"worst" model; that is, the model with the highest rms difference between the calculated and experimental
result. (A) Relationship between experimental and calculated absolute Ca chemical shifts. (B) Comparison of
experimental and calculated Ca secondary chemical shifts.
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Figure 31 Conserved 6-residue structural motifs. Helical conformations are colored purple and extended
regions are shown in cyan. The region corresponding to a turn is colored yellow.
128
AC
PCNA-bound p21
(crystal structure):
B
P-/~
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164
Ill lll I IIllllllll II I
Corresponding local
conformational
Preference (EMW):
Figure 32 A) X-ray crystallographic structure of a p21 model peptide (residues 139-160) bound to PCNA
[PDB ID 1AXC [253]]. The helical region (p21 residues 146 - 151) is highlighted in purple, while the extended
C-terminus (p21 residues 152 - 160) is depicted in cyan. Only residues of p21 included in our model peptide
(145-160) are shown. B) Structure of the p21 model peptide alone. C) Comparison of corresponding local
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unbound form include local conformations which match the bound form crystal structure are indicated.
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Figure 33 Determination of the CaM/p21 binding mode using RDCs. Best-fitting of observed backbone RDCs
of the Ca +-CaM/p21(145-164) complex to (A) the free Ca2+-CaM crystal structure (PDB code: 1EXR) and (B)
the crystal structure of Ca 2+-CaM/CaMKII (PDB code: ICDM). All RDCs are normalized to 1DNH.
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-Erwin Schrbdinger, My View of the World
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